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1 Summary 
Erythropoiesis is considered as a multistep and tightly regulated process under the 
control of a series of cytokines including erythropoietin (Epo). Epo activates specific 
signaling pathways and key transcription factors such as GATA-1, in order to ensure 
erythroid differentiation. Dysregulation leads to a decreased number of red blood 
cells, a hemoglobin deficiency, thus a limited oxygen-carrying capacity in the blood. 
Anemia represents a frequent complication in various diseases such as cancer or 
inflammation related disease. Tumor necrosis factor alpha (TNFα) was described to 
be involved in the pathogenesis of inflammation and cancer related anemia, which 
reduces both quality of life and prognosis in patients. Blood transfusions and 
erythroid stimulating agents (ESAs) including human recombinant Epo (rhuEpo) are 
currently used as efficient treatments. However, the recently described conflicting 
effects of ESAs in distinct studies require further investigations on the molecular 
mechanisms involved in TNFα-caused anemia. 
The aim of this study was to reveal the molecular mechanisms linked to the 
inhibition of erythroid differentiation by the proinflammatory cytokine TNFα. In 
order to achieve this goal, we used three different hematopoietic cell lines (K562, 
HEL, and TF-1) as well as purified CD34+ hematopoietic progenitor cells from 
umbilical cord blood. For K562 and HEL cells, distinct chemical compounds such as 
Aclacynomicin (Acla), Doxorubicin (Dox), or Hemin (He) were used to induce 
erythroid differentiation, whereas TF-1 and CD34+ cells were treated with Epo. 
Results showed an inhibitory effect of TNFα on hemoglobin synthesis in the 
different cellular models, independently of the inducer used. This effect was 
correlated with a decrease of the major erythroid transcription factor GATA-1 and its 
coactivator Friend of GATA-1 (FOG-1). We further demonstrated that the reduction 
of the GATA-1/FOG-1 complex was partly due to a proteasome-dependent 
degradation of the interaction partners. Moreover, an unsettling of the 
complementary expression profiles of GATA-1 and GATA-2 in the three cell lines 
tested was observed, which is in disfavor of final erythroid differentiation. The 
observed abolishment of the acetylation status of GATA-1 by TNFα in He-induced 
K562 cells even suggested an impact of the cytokine on GATA-1 transcriptional 
activity. As assessed by transfection experiments, TNFα had also an inhibitory effect 
on GATA-1 transactivation activity, independently of the inducer used. Then we 
analyzed the expression of specific marker genes partly known as GATA-1 target 
genes. Results revealed a decrease in Epo receptor (EpoR), α- and γ-globin, 
erythroid-associated factor (ERAF), hydroxymethylbilane synthetase (HMBS), and 
glycophorin A (GPA) expressions after TNFα treatment. Furthermore, we showed 
that p38 is involved in the TNFα-mediated inhibition of Epo-triggered erythroid 
differentiation, as the p38 inhibitor SB203580 reverses the inhibition of hemoglobin 
production, γ-globin gene and GATA-1 expression.  
These data contribute to a better understanding of the molecular mechanisms 
involved in cytokine-dependent anemia both by revealing modulations of key 
erythroid transcription factors as well as potential diagnostic markers. Overall this 
study gives first hints of the key players involved in TNFα-mediated inhibition of 
erythroid differentiation, which can be seen as foundation for future investigations. 
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1.1 Zusammenfassung 
Die Erythropoese stellt einen mehrstufigen, streng regulierten Prozess dar, der durch 
Erythropoetin (Epo) und andere Zytokine gesteuert wird. Epo aktiviert bestimmte 
Signaltransduktionswege und Transkriptionsfaktoren (TF), wie z.B. TF GATA-1, der 
eine entscheidende Rolle als Regulator der Erythrozytendifferenzierung spielt. Eine 
Deregulierung dieser Schlüsselfaktoren kann zur Reduzierung der roten 
Blutkörperchen führen, was mit einer Hämoglobindefizienz und somit einer 
verminderten Sauerstoff-Transportkapazität im Blut einhergeht. Die Anämie stellt 
eine häufig auftretende Komplikation bei Krebs- oder Entzündungserkrankungen 
dar. Der Tumornekrosefaktor alfa (TNFα) ist ein Hauptmediator von Entzündungs-
krankheiten und wurde in der Pathogenese von diversen entzündungs- sowie bei 
krebsbedingten Anämien beschrieben,  wodurch sowohl die Lebensqualität als auch 
die Prognose des Krankheitsverlaufes beeinträchtigt wird. Vor der Verwendung von 
Erythropoese stimulierenden Agenzien (ESAs) waren Bluttransfusionen die einzige 
verfügbare Therapie. Die kürzlich diskutierten, z.T. widersprüchlichen 
Therapieergebnisse der ESAs machen die Erforschung der molekularen 
Mechanismen, die mit der genannten Anämie assoziiert sind, notwendiger denn je. 
Ziel dieser Studie ist es, molekulare Mechanismen, zu entschlüsseln, die der 
Hemmung der Erythropoese durch das proinflammatorische Zytokin TNFα zugrunde 
liegen. Hierfür wurden verschiedene zelluläre Modelle verwendet. Hämatopoetische 
Zelllinien (K562, HEL) wurden durch chemische Verbindungen wie Aclacynomicin 
(Acla), Doxorubicin (Dox) oder Hemin (He) zur Erythropoese angeregt, wohingegen 
TF-1 Zellen oder aus Nabelschnurblut isolierte, hämatopoetische Vorläuferzellen 
(CD34+) mit Epo behandelt wurden. Nach Zugabe von TNFα wurde dessen 
inhibitorischer Effekt auf die Hämoglobinsynthese in allen Modellen sichtbar. Dieser 
Effekt ging in allen untersuchten Zelllinien mit einer Reduktion der GATA-1- und 
FOG-1-Proteine einher. Der Rückgang des GATA-1/FOG-1 Interaktionskomplexes 
nach TNFα-Zugabe ließ sich auf einen Proteasom-abhängigen Abbau der 
Interaktionspartner zurückführen. Ferner wurde eine Veränderung der 
komplementären Expressionsprofile von GATA-1 und GATA-2 beobachtet, was 
dem Differenzierungsprozess entgegensteht. Eine Veränderung des Acetylierungs- 
status von GATA-1 in He-behandelten K562 Zellen nach TNFα Zugabe ließ einen 
Einfluss des Zytokins auf die transkriptionelle Aktivierung von GATA-1 vermuten. 
Diese Theorie unterstützend zeigte TNFα, unabhängig vom benutzten Induktor, 
einen inhibitorischen Effekt auf die transkriptionelle Aktivität von GATA-1. Eine 
erythroidbezogene Markergen-Analyse zeigte nach TNFα-Zugabe eine 
Expressionsreduzierung folgender Gene: Erythropoetin Rezeptor, α- und γ-Globin, 
Erythroid-assoziierter Faktor, Hydroxymethylbilan Synthetase und  Glykophorin A. 
Gleichzeitig konnte in TF-1 Zellen mit Hilfe eines p38-Inhibitors die Beteiligung 
von p38 an der TNFα-getriggerten Hemmung auf verschiedenen Ebenen 
(Hämoglobinsynthese, GATA-1- und γ-Globin-Proteinexpression) gezeigt werden.  
Die Ergebnisse führen zu einem besseren Verständnis der molekularen 
Mechanismen, die der Zytokin-abhängigen Anämie zugrunde liegen. So wurden 
Veränderungen im Transkriptionsfaktorprofil, sowie in der Expression verschiedener 
potentieller diagnostischer Markergene festgestellt. Insgesamt enthüllt diese Studie 
erste vielversprechende Erkenntnisse über verschiedene Schlüsselelemente, die in 
der Hemmung der Erythropoese durch TNFα eine entscheidende Rolle spielen.
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2 Introduction 
2.1 Erythropoiesis 
2.1.1 Regulation of erythropoiesis 
Erythropoiesis is commonly considered as a multistep event leading from hematopoietic 
stem cells (HSC) to the formation of erythrocytes. These reside in the bone marrow and 
have the unique ability to give rise to the different mature hematopoietic cells, which are 
usually classified into two distinct lineages, the lymphoid and the myeloid.  
 
 
Figure 1: Hematopoiesis and the role of cyokines. Cytokines act both on multipotential 
progenitors and their committed offspring. Yellow squares emphasize the cross-antagonistic 
role of the transcription factors GATA-1 and PU.1 in myeloid versus lymphoid commitment. 
BCP, B-cell progenitor; CLP, common lymphoid progenitor; CMP, common myeloid 
progenitor; HSC, hematopoietic stem cell; GMP, granulocyte–macrophage progenitor; MEP, 
megakaryocyte erythroid progenitor; MPP, multipotent progenitor; TNK, T-cell natural killer 
cell progenitor; IL, Interleukin; SCF, stem cell factor; GM-CSF, granulocyte-macrophage 
colony stimulating factor; G-CSF, granulocyte colony stimulating factor; M-CSF, macrophage 
colony stimulating factor; TPO, thrombopoietin, Epo, Erythropoietin. (Adapted from Robb et al. 
and Wickrema et al.  1,2) 
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Erythroid differentiation arises from the myeloid root and is phenotypically 
characterized by the production of hemoglobin synthesis and expression of erythroid 
markers such as hydroxymethylbilane synthase (HMBS), Erythroid-associated factor 
(ERAF), transferrin receptor (TFRC), globins and glycophorin A (GPA). Hematopoiesis 
is regulated by distinct cytokines acting on both multipotential progenitors and their 
committed offspring 1,2. Ferrous iron (Fe2+) is also essential for erythropoiesis as a major 
component of heme in hemoglobin and in the redox system of the respiratory chain. 
Hepcidin, a 25-amino acid peptide, is the main regulator of iron transport. During 
differentiation from a multipotent common myeloid progenitor (CMP) to a bipotent 
megakarocyte erythroid progenitor (MEP), burst-forming units erythroid (BFU-E) and 
colony forming units erythroid (CFU-E) are the earliest identifiable erythroid 
progenitors in culture and are characterized by their in vitro ability to form colonies 3 
(Fig. 1).  
Erythropoiesis is a very dynamic and tightly regulated process by which 2*1011 
erythrocytes (lifespan of 100 days) are produced every day 4. A feedback loop involving 
the major cytokine for human erythropoiesis, erythropoietin (Epo), is regulating this 
physiological process. The kidney and the liver are the main sites that produce the 
glycoprotein hormone Epo in adult humans. The rate of expression of the Epo gene 
depends on the level of tissue oxygen through the availability of the hypoxia inducible 
factor (HIF), which acts as a global transcriptional regulator, thus as a sensor of oxygen 
homeostasis. Indeed, there are essential HIF binding sites in the Epo enhancer, which in 
hypoxic conditions are bound by the HIF heterodimer, consisting of the oxygen 
sensitive HIF-1α and the constitutively expressed HIF-1β subunit. Changes in 
circulating Epo, its function, or its action can lead to major changes in the number of 
erythrocytes. Oxygen-dependent prolyl hydroxylases control Epo variations in the 
kidney by regulating the stability of HIF-1α.  
Erythroid differentiation can be considered as a finely triggered balance between 
positive signals constituted by Epo and stem cell factor (SCF) and negatively influenced 
by death receptor ligands and inhibitory cytokines. Epo acts through its receptor (EpoR) 
in order to stimulate various underlying cell signaling pathways including the 
Phosphotidylinositol 3 kinase (PI3K), the Janus kinase/Signal-transducer and activator 
of transcription (JAK/STAT) and the mitogen-activated protein kinase (MAPK)/ 
extracellular signal-related kinase (ERK) pathways 5. Like Epo and EpoR, GATA-1 is 
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considered as an essential transcription factor for the survival of erythroid precursors 
and their terminal differentiation into red blood cells. It has been reported that Epo 
modulates GATA-1 function in erythroid cells 6 (Fig. 1).  
Dysregulation of Epo or other key factors of erythroid differentiation can either lead to 
major changes in red blood cell number and subsequently the oxygen-carrying capacity 
of the blood. Erythrocytoses are disorders resulting in an excessively high level of 
erythrocytes, whereas anemia is characterized by a qualitative or quantitative deficiency 
of hemoglobin and is clinically defined as an hemoglobin (Hb) level ?12g/dL.  
2.1.2 Transcription factors involved in erythropoiesis 
Erythrocytes were described to result from passage through cellular hierarchies 
dependent on differential gene expression under the control of complex transcription 
factor networks responsive to changing niches 7. In this regard, a key regulator of 
erythroid development that plays a central role in red cell gene expression is the 
transcription factor GATA-1. GATA-1 null mouse embryos die between E10.5 and 
E12.5 from severe anemia due to a complete ablation of embryonic erythropoiesis 8, and 
GATA-1-/- embryonic stem cells cannot contribute to definitive erythropoiesis 9.  
GATA-1 is a member of the GATA family, which includes 6 members (GATA-1 to 
GATA-6). These transcription factors recognize the same DNA consensus sequence 
(A/T)GATA(A/G) and present two characteristic zinc finger motifs specific to the 
GATA family 10-13. The GATA family can be divided in two subfamilies on the basis of 
the expression of the individual transcription factors. GATA-1, GATA-2, and GATA-3 
belong to the hematopoietic, whereas GATA-4, GATA-5, and GATA-6  belong to the 
nonhematopoietic subfamily 14,15. GATA-1 was first identified as a protein with binding 
capacity to the β-globin promoter 16. It is expressed in various cells such as primitive 
and definitive erythroid cells 8,17, megacaryocytes 18,19, eosinophils 20, mast cells 18, and 
Sertoli cells from testis 21. GATA-1 protein revealed at least three functional domains: 
the N-terminal activation domain, the N-terminal Zinc finger (N-finger) and the C-
terminal Zinc finger (C-finger). The C-finger is essential for binding to the GATA 
consensus sequence of the DNA 10,22. The N-finger supplies the stabilization and 
specificity of DNA binding, and is responsible for the interactions with cofactors such 
as Friend of GATA-1 (FOG-1) for example 10,13,23-25.  
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Regulation of erythroid and megakaryocytic gene expression requires a combination and 
cooperation of specific hematopoietic transcription factors including NF-E2 (Nuclear 
Factor Erythroid-2), described to act as a major regulator of hemoglobin synthesis 
during erythropoiesis 26, and EKLF (erythroid Krüppel-like factor), a crucial factor in 
erythroid and megakaryocytic differentiation and maturation (Fig. 2).  
 
 
Figure 2: Stages of mammalian hematopoiesis: (A) The relative sizes and the known or 
presumed morphologic appearances of erythroid cells at various stages of differentiation: 
pluripotent hematopoietic stem cell (HSC), burst-forming units-erythroid (BFU-E), colony-
forming units-erythroid (CFU-E), proerythroblasts (Pro EB), basophilic erythroblasts (Baso 
EB), polychromatophilic erythroblasts (Poly EB), orthochromatic erythroblasts (Ortho EB), 
reticulocytes (RET), and erythrocytes (RBC). (B) Erythroid transcription factors: basic helix-
loop-helix factor (TAL1); Lim-domain partner of TAL1 (LMO2); zinc finger factors that bind 
GATA sequences (GATA-1, GATA-2); GATA-1 cofactor, friend of GATA (FOG-1); 
retinoblastoma protein (RB); erythroid Kruppel-like factor (EKLF); and nuclear factor 
erythroid2 (NF-E2). (C) Receptors for hematopoietic growth factors: stem cell factor-
receptor/c-KIT, erythropoietin receptor (EpoR). (D) Proteins related to erythrocyte structure 
and function: periods of expression for erythroid-specific forms of proteins are shown; 
transferrin receptors (TFRC) are present in all stages, but period of large upregulation is 
shown. For each transcription factor, growth factor receptor, and erythrocyte-related protein, 
the degree of expression can vary significantly during the period shown. Expression of factors 
analyzed in this study are highlighted in orange. (Adapted from Koury et al. 27) 
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Positive and negative interactions with transcriptional cofactors as well as 
autoregulatory mechanisms contribute to GATA-1 activity leading to transcription of 
hematopoietic lineage-specific genes including globins, Epo receptor (EpoR), 
porphobilinogene deaminase, GPA and transcription factors such as erythroid Kruppel-
like factor (EKLF) and GATA-1 itself (Fig. 2). Thus, FOG-1 28,29, CBP/p300 30, Friend 
leukemia integration 31 are positive cofactors of GATA-1 activity whereas PU.1 (Sp1) 
and pRB 32, the hairy-enhancer-of-split-related factor 33 and Ski 34 have been described 
as negative regulators of GATA-1. FOG-1 is expressed simultaneously with GATA-1 in 
erythroid and megakaryocytic lineages and cooperates with this major erythroid 
transcription factor during erythroid and megakaryocytic development 28. FOG-
1/GATA-1 has been shown to be essential for GATA-1 function during erythroid 
differentiation, since GATA-1 mutants were defective in FOG-1 binding 35. Furthermore 
FOG-1 was shown to differentially modulate GATA-1 activity depending on the 
promoter context 28,36,37. PU.1 is an Ets family member of transcription factors 
responsible for the myeloid lineage commitment. GATA-1 and PU.1 have cross-
antagonistic relationships, thus they seem to functionally antagonize each other via 
direct physical interaction of their DNA-binding domains 38,39 (Fig. 1). GATA-1 inhibits 
PU.1 by preventing its interaction with c-Jun, while PU.1 impairs GATA-1 by inhibiting 
its binding to DNA 37,40.  
GATA-1 and GATA-2 are both expressed in erythrocyte and megacaryocyte lineages 
and present overlapping but distinct expression patterns. During early hematopoiesis, 
GATA-2 is involved in expanding progenitor cells, while GATA-1 is required for 
terminal erythroid maturation 41. On the other hand, transcription factors such as nuclear 
factor, erythroid derived 2 (NF-E2) or EKLF, which act downstream of GATA-1 are 
required for globin gene expression 7,42,43.  
GATA-1 is also regulated by posttranslational mechanisms. GATA-1 has been shown to 
be acetylated by the ubiquitously expressed acetyltransferases p300 44 and CREB-
binding protein 45. The function of GATA-1 acetylation remains partially unclear. The 
interaction between p300/CBP and GATA-1 and the subsequent acetylation of GATA-1 
seems to stimulate transcriptional activity 30,44. GATA-1 can also be phosphorylated 46 
and sumoylated 47. Hernandez-Hernandez et al. suggested that acetylation of GATA-1 
positively signals ubiquitination, and that MAPK phosphorylation then assists with 
acetylation to perform definitive protein degradation 48. GATA-1 protein degradation, 
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another possible regulatory mechanism, has also been previously reported via caspase 
cascade or the proteasome 49,50. 
2.2 Tumor necrosis factor alpha 
Tumor necrosis factor alpha (TNFα), also known as cachectin or differentiation 
inducing factor, is a proinflammatory multifunctional cytokine, which is mainly 
produced by macrophages, but also by neutrophiles, fibroblasts, keratinocytes, 
astrocytes, Kupffer cells, smooth-muscle cells, T and B cells. It was initially described 
to induce hemorrhagic necrosis in transplanted tumors 51. Its effects are principally 
mediated through two distinct receptors TNFα receptor I (TNFRI) (p55) and TNFα 
receptor II (TNFRII) (p75) before stimulating various underlying cell signaling 
pathways including nuclear factor kappa B (NF-κB), c-Jun N-terminal kinase (JNK), 
p38, or caspase activation. Thus TNFα simultaneously activates both apoptotic and anti-
apoptotic or cell survival signals depending on the factors present in the receptor 
complex 52. TNFα is known as the most powerful activator of NF-κB, which was 
discovered as a factor in the nucleus of B cells that binds to the enhancer of the kappa 
light chain of immunoglobulin 53. The NF-κB family consists of Rel-domain-containing 
proteins: Rel A (also called p65), Rel B, c-Rel, p50 (also called NF-κB1), and p52 (also 
called NF-κB2). Inactive NF-κB is kept in the cytoplasm of cells by a family of 
anchorin-domain containing proteins, inhibitor of NF-κB family (IκB family). When 
TNFα binds to and trimerizes its receptor, distinct factors are recruited forming a 
receptor complex, which activates the Inhibitor of κB kinase (IKK) 54. Activated IKK 
then phosphorylates IκBα, which is ubiquitinated and degraded, thus releasing p50-p65 
heterodimer, which then translocates to the nucleus, binds its specific ten base pair 
consensus binding site and regulates over 200 immune, growth, and inflammation genes 
55. 
As TNFα as well as other TNFα superfamily members play a role in hematopoiesis, 
host defense, immune surveillance, and proliferation, its deregulation leads to numerous 
diseases, including cancer 52,56,57. Indeed, TNFα expression has been confirmed in the 
tumor microenvironment of various malignancies 58. Indeed, this cytokine is 
paradoxically able to induce necrosis and to promote tumor development, depending on 
the levels of TNFα in distinct settings 59. When TNFα is secreted by tumors and tumor-
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associated macrophages at physiological levels, it promotes tumor growth and 
stimulates angiogenesis, whereas when administered therapeutically at high doses, it 
induces an increased permeability of tumor vasculature. Thus, recombinant TNFα, as a 
tumor regressing agent, is approved in Europe to be administered locoregionally at 
supraphysiological levels as a therapy for soft tissue sarcoma 60-63.  
2.2.1 TNFα and inflammation  
A TNFα overproduction generates numerous chronic inflammatory diseases, such as 
rheumatoid arthritis 64-66 chronic hepatitis C 67, or Crohn's disease 68,69. An increase in 
the TNFα level was described in diabetic patients to cause retinopathies 70-75, while 
during pancreatitis, released TNFα leads to inflammation and cellular damage 76.  
Currently, three marketed TNFα antagonists [etanercept (Enbrel®), infliximab 
(Remicade®), and adalimumab (Humira®)] are indicated in a variety of diseases 
characterized by abnormally elevated TNFα levels such as rheumatoid arthritis (RA), 
psoriatic arthritis, ankylosing spondylitis, Juvenile rheumatoid arthritis, and Crohn’s 
disease, whereas the effectiveness of the treatments varies with agent and disease 77,78. 
TNFα is thus leading to various biological phenomena implying different molecular 
mechanisms and is involved in various cellular responses. Although TNFα is considered 
to act as a proinflammatory cytokine, it was described both as a positive and negative 
regulator of myeloid cell proliferation and differentiation 79-87. Effects of TNFα can be 
mediated either directly 83,88,89 or indirectly by inducing other cells to produce 
cytokines, including hematopoietic growth factors 90-94.  
2.2.2 Link between TNFα, cancer and inflammation 
Furthermore TNFα plays an interesting as well as complex function in cancer. 
Considering its role as a proinflammatory cytokine, the investigation of a murine model 
of inflammation-associated hepatocellular carcinogenesis involved activation of the 
tumor promoter NF-κB via production of inflammatory TNFα 95. Moreover several 
reports associated detection of abnormally high levels of TNFα protein and/or 
constitutively active NF-κB in cancer patients with a wide range of tumor types 96, 
including kidney 97, breast  98,99, asbestosis induced lung 100, and prostate cancers 101,102. 
Suppression of constitutively active NF-κB resulted in cell proliferation arrest and 
apoptosis indicating a crucial role for NF-κB in proliferation and survival 55. 
Furthermore chronic bioaccessibility of TNFα has been correlated with enhanced 
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invasive activities as well as survival of neoplastic cells 59. Within groups of patients 
with the same tumor type, higher levels of TNFα have been correlated with advanced 
tumor stage, greater complications, and shorter survival time 103. Moreover various 
cytokines, including TNFα, are overexpressed in pancreatic cancer cells, leading to an 
NF-κB activation and as a consequence, to cell growth by inhibiting apoptosis 104,105. 
TNFα also appears as a growth factor regulated by NF-κB in Hodgkin’s lymphoma, T 
cell lymphoma and glioma 106.  
As Rudolf Virchow already suspected in 1863, inflammation and cancer cannot be 
handled separately anymore 107-109. It was demonstrated that cancer-associated 
inflammation could even promote tumor growth 95,107,110. Indeed cancer-associated 
inflammation includes the expression of cytokines such as TNFα or IL-1 by tumor-
associated macrophages, stimulating tumor growth 111. Indeed, as TNFα was even 
categorized as a tumor promoter, it is not astonishing that cytokine antagonists as well 
as NF-κB inhibitors are already used in cancer therapy and prevention 59,112-115.  
2.3 Link between erythropoiesis and TNFα 
Besides the proinflammatory, proliferative and apoptotic properties, TNFα was also 
described as an inhibitor of the erythroid differentiation in vitro and in vivo 80,81,84,89,116-
122. Its expression is associated with several hematologic diseases such as Fanconi 
anaemia (FA) 123,124, myelodysplastic syndromes 125, aplastic anemia 123,126 and anemia 
due to chronic diseases 94,127,128. Indeed, in FA patients, TNFα is significantly 
overexpressed in stimulated marrow mononuclear cells, which leads to a suppression of 
erythropoiesis. In bone marrow cultures, the addition of anti-TNFα increases the size 
and the number of CFU-E and BFU-E grown from FA patients but not from healthy 
controls. This indicates that FA subjects have a marrow TNFα activity that inhibits 
erythropoiesis in vitro. TNFα plays a relevant role in the pathogenesis of erythroid 
failure in FA patients 124. Several in vitro studies revealed the inhibitory effects of this 
cytokine on hematopoietic progenitor cell growth 80,81,84,89,118,124,129. It was shown that 
the inhibition of human CFU-E by TNFα requires beta interferon, which is produced by 
macrophages in response to TNFα 94. TNFα was also shown to have a direct inhibitory 
effect on Epo-induced generation of GPA positive cells from CD34+ progenitors, 
leading to a suppression of erythropoiesis and a reduction of the proliferation capacity of 
GPA+ cells 129.  
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Interestingly, TNFα is also believed to play a critical role in many forms of cancer 130,131 
and inflammation related anemia 132-135. Indeed anemia is considered as a common 
symptom induced by inflammation and cancer pathologies. In patients with B-cell 
chronic lymphocytic leukemia suffering from anemia, the serum levels of TNFα were 
significantly higher than in those without anemia 136. The incidence of anemia was 
shown to vary with tumor type, stage and patient age. Up to one third of patients are 
suffering from anemia at diagnosis 137, a number, which increases after chemotherapy 
138. Cancer-associated anemia can be considered as a negative prognostic factor for 
survival regardless of tumor type 139 (Fig. 3). Moreover, the quality of life is 
considerably affected and is associated with a range of symptoms including fatigue, 
depression, and dizziness 140; thus pro-inflammatory cytokines were recently suggested 
as the common denominator for cancer related fatigue 141. 
 
 
Figure 3: Pathophysiology of anemia. Tumor cells act on erythrocytes by affecting cell 
survival and trigger cytokine release through macrophages, which leads to impaired 
erythropoiesis. TNFα, tumor necrosis factor alpha; IFN, Interferon; IL, Interleukin; HIF, 
hypoxia inducible factor; BFU-E, burst-forming units-erythroid; CFU-E, colony-forming units-
erythroid, Epo, Erythropoietin. (Adapted from Engert et al. 142 ) 
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Regarding anemia due to inflammation, this sign of ineffective erythropoiesis was 
described as a clinical entity of patients with inflammatory disorders 143. Prior to the use 
of erythroid stimulating agents (ESAs), blood transfusions were the only treatment for 
cancer related anemia. However, the recently described conflicting effects of ESAs in 
distinct studies 144-146 as well as the tremendous costs related to this treatment, make it 
necessary to further investigate the molecular mechanisms involved in anemia and to 
identify new targets for drug development as well as to detect more significant 
predictors for anemia. In order to improve quality of life, several drugs are under 
investigation for the treatment of different forms of anemia. In this context Jelkmann 
reviewed several anti-anemic drugs and techniques based on Epo gene expression 147,148. 
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3 Aim  
The proinflammatory cytokine TNFα was linked to the pathogenesis of inflammation 
and cancer related anemia, which reduces both quality of life and prognosis of patients.  
In order to investigate the mechanisms involved in the inhibition of erythroid 
differentiation by TNFα, the objectives of the present study were: 
 to investigate the effect of TNFα on human leukemia cell lines K562, HEL, TF-1 
as well as umbilibal cord blood CD34+ cells stimulated by distinct chemical 
agents or Epo  
 to analyze the effect of NF-κB induction in our cellular models 
 to study the expression profiles of major erythroid transcription factors after 
TNFα addition 
 to evaluate the effect of TNFα transactivation activity of the key erythroid 
transcription factor GATA-1 
 to examine the variations of GATA-1 target genes after cytokine treatment 
 to reveal possible signaling pathways involved in the TNFα-mediated inhibition 
of erythroid differentiation 
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4 Materials and methods 
4.1 Materials 
Chemicals  
1-bromo-3-chloro-propane Sigma 
2-mercaptoethanol Merck 
Acetic acid MP Biomedicals 
Agarose MP Biomedicals 
Alexa Fluor® 488 donkey anti-goat IgG 
(H+L) 
Invitrogen 
Ammonium persulfate MP Biomedicals 
Amphotericin MP Biomedicals 
Ampicillin Sigma 
Antibody anti-acetyl-Lysine (4G12) 
monoclonal mouse IgG 
Upstate 
Antibody anti-β-actin mouse monoclonal 
IgG (A5441) 
Sigma 
Antibody anti-EpoR rabbit polyclonal IgG 
M-20 (sc-697) 
Santa Cruz Biotechnology 
Antibody anti-EpoR rabbit polyclonal IgG 
C-20 (sc-695) 
Santa Cruz Biotechnology 
Antibody anti-FOG-1 goat polyclonal IgG 
M-20 (sc-9361) 
Santa Cruz Biotechnology 
Antibody anti-γ-globin mouse monoclonal 
IgG (51-7) (sc-21756) 
Santa Cruz Biotechnology 
Antibody anti-GATA-1 goat polyclonal 
IgG C-20 (sc-1233X) 
Santa Cruz Biotechnology 
Antibody anti-GATA-1 rat monoclonal 
IgG N-1 (sc-266) 
Santa Cruz Biotechnology 
Antibody anti-GATA-2 rabbit polyclonal 
IgG (H-116) (sc-9008) 
Santa Cruz Biotechnology 
Antibody anti-GPA goat polyclonal IgG 
(E-18) (sc-19451) 
Santa Cruz Biotechnology 
Antibody anti-phospho-p38 rabbit 
polyclonal IgG (9211)  
Cell signaling 
Antibody anti-p38 rabbit polyclonal IgG  
(9212)  
Cell signaling 
Antibody anti-p50 rabbit polyclonal IgG 
(H-119)  (sc-7178X) 
Santa Cruz Biotechnology 
Antibody anti-p65 rabbit polyclonal IgG 
(C-20) (sc-372X) 
Santa Cruz Biotechnology 
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Antibody anti-PU.1 rabbit polyclonal IgG 
(Spi-1, T-21) (sc-352) 
Santa Cruz Biotechnology 
Aprotinine Roche 
Benzidine Fluka 
Bradford solution Bio-Rad 
Bromophenol blue LKB  
BSA MP Biomedicals 
CD34 Microbead Kit human Miltenyi Biotec  
CD-34 monoclonal mouse anti-human 
reagent (FITC) 
BD Biosciences 
CD-45 monoclonal mouse anti-human 
reagent (PerCP) 
BD Biosciences 
CO2 Air liquide 
Complete Protease Inhibitor Cocktail 
Tablets 
Roche 
Cytofix/Cytoperm kit  BD Biosciences 
Donkey anti-goat IgG HRP (sc-2020) Santa Cruz Biotechnology 
Donkey anti-goat Alexafluor 488 Molecular probes 
Donkey anti-rabbit IgG HRP (sc-2313) Santa Cruz Biotechnology 
1,4-Dithiothreitol (DTT) MP Biomedicals 
Dual Glo Luciferase Assay System Promega 
ECL + Lumigen PS-3 detection reagent GE healthcare 
EDTA  MP Biomedicals 
Ethylene glycol-bis-N,N,N’, N’-tetraacetic 
acid (EGTA) 
Sigma 
Ethanol Prolabo 
Ether Merck 
ethidium bromide aqueous solution Sigma 
FCS Cambrex 
Ficoll-Paque Premium GE healthcare 
Formaldehyd MP Biomedicals 
Formamid MP Biomedicals 
γ-32P-phosphate MP Biomedicals 
Glycerol (87%) Merck 
Glycerol bidistilled VWR International 
Glycine electrophoresis grade MP Biomedicals 
Goat anti-mouse IgG-HRP (sc-2005) Santa Cruz Biotechnology 
Goat anti-rat IgG-HRP (sc-2006) Santa Cruz Biotechnology 
H2O2 Sigma 
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Heparin Braun 
Hepes free acid MP Biomedicals 
Igepal  MP Biomedicals 
Isopropanol VWR international 
KCl Merck 
KH2PO4 VWR International 
KOH Merck 
LB Agar, Miller MP Biomedicals 
LB Broth, Miller MP Biomedicals 
Leupeptine Merck 
Liquid-gel 29:1 MP Biomedicals 
Liquid-gel 37.5:1 MP Biomedicals 
Methanol MP Biomedicals 
Milk group Auchan 
Na2HPO4 MP Biomedicals 
NaCl MP Biomedicals 
NF-κB p50 rabbit polyclonal IgG Santa Cruz Biotechnology 
NF-κB p65 rabbit polyclonal IgG Santa Cruz Biotechnology 
Nucleobond AX Macherey-Nagel 
O-phenylanthroline Sigma 
Orthovanadate Calbiochem 
Penicillin Sigma 
Penicillin-streptomycin-fungizone mixture Cambrex 
Phenylmethylsufonylfluoride (PMSF) Roche 
Poly-dIdC Roche-Prophac 
Protease inhibitor cocktail tablets  Roche 
Qiaquick Removal Nucleotide kit Qiagen 
Renilla Luciferase reporter vectors (phRL-
SV40) Promega 
RNeasy Mini kit  Qiagen 
RPMI medium Cambrex-Lonza 
RT-PCR kit Invitrogen 
RT2PCR Array First strand kit (C-02) SuperArray 
SDS 20% MP Biomedicals 
Spermidine MP Biomedicals 
Stem line medium II Sigma 
Streptomycin Sigma 
T4 Polynucleotide kinase & kinase buffer Roche 
Tetrametylethyldiamine (Temed) MP Biomedicals 
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TransAM kit Active Motif 
Tris MP Biomedicals 
Triton X-100 Merck 
TRIzol  Invitrogen 
Trypan Blue Cambrex 
Tween 20 MP Biomedicals 
Xylene cyanole MP Biomedicals 
 
Erythroid differentiation inducers and treatment agents  
Aclacynomicin A Sigma 
Aclacynomicin A Hydrochloride Sigma 
Bay11-7082 (inhibitor of nuclear factor κB 
(NF-κB) activation) 
Calbiochem 
DMSO MP Biomedicals 
Doxorubicin Hydrochloride MP Biomedicals 
Epo (Eprex) Jansson-Cilag 
Granulocyte/macrophage colony 
stimulating factor (GM-CSF) 
Pepro Technology 
Hemin MP Biomedicals 
IL-3 Pepro Technology 
JNK inhibitor (SP600125) Calbiochem 
Lactacystin Sigma 
MEK inhibitor (PD98059) Calbiochem 
MEK inhibitor (U0126) Promega 
P38 inhibitor (SB203580) Promega 
PI3K inhibitor (Ly 294002) Calbiochem 
Remicade Centocor 
SCF Pepro Technology 
TNFα Pepro Technology 
 
DNA markers  
100 base pair ladder Invitrogen 
Kaleidoscope Prestained Standards Bio-Rad 
 
Instruments  
7300 real-time PCR system Applied Biosystems 
96-well plate Greiner 
96-well plate reader Packard, Perkin Elmer 
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Autoradio cassette  GE healthcare 
Autoradiography development machine 
Curix 60 AGFA 
Balance Ohaus 
Bioanalyzer Agilent 
Biorad Gene Pulser II Bio-Rad 
Centrifuge 5415  Eppendorf 
Centrifuge 5415 D Eppendorf 
Centrifuge 5810  Eppendorf 
Centrifuge KR 25 Jouan 
CO2 incubator Jouan 
Electrophoresis apparatus Biometra 
FACS Calibur BD Biosciences 
Freezer -80 °C Jouan 
Gel dryer Bio-Rad 
Generator Biometra 
Heating plate IKA 
Hood Microflow/FluFrance/ClearAir 
Liquid-nitrogen tank  Taylor-Wharton 
µMACS Separator Sarting Kit Miltenyi Biotec 
MACS µ Columns Miltenyi Biotec 
MACS pre-Separation Filters Miltenyi Biotec 
MACS protein G Microbeads Miltenyi Biotec 
MACS (MidiMACS) Starting Kit Miltenyi Biotec 
Malassez chamber Marienfeld 
Material for gelshift Bio-Rad 
Material for western blot Bio-Rad 
Microscope Leica 
Microscope Nikon 
Microwave Severin 
MilliQ machine  Millipore 
Mini centrifuge National Labnet Co. 
Nanodrop ND-1000 Nanodrop technologies 
Nucleofector Amaxa 
Orion microplate luminometer Berthold 
PCR Mastercycler Eppendorf 
Petri dish Greiner 
PH meter Eutech Instruments 
PhosphorImager Cyclone Packard, Perkin Elmer 
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Photo film (GS) Kodak 
Photo film (western blot) GE healthcare 
Pipet-aid Falcon 
Pipettes Gilson 
Plexiglas protection shields Nalgene 
Precision balance  Ohaus 
PVDF membrane GE healthcare 
Roller Mixer SRT2 Stuart Scientific 
Speedvac Jouan 
Spectrophotometer Pharmacia Biotech 
Transfert instrument (western blot) Bio-Rad 
Vortex Scientific industries 
Water bath GFL 
 
Software  
Elisa reader Reader  
Gel camera  LabWorks Gel-Pro application 
Gelshift phosphoimager Cyclone OptiQuant 
Quantification program Kodak 1D 3.5 
Microscope Leica, Image J 
 
Cell lines and bacteria  
HEL DSMZ 
K562 DSMZ 
TF-1 DSMZ 
TOP 10F’ one shot bacteria Invitrogen 
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4.2 Cells     
4.2.1 Cell lines 
• The human chronic myeloid leukemia (CML) K562 cell line (Deutsche Sammlung 
von Microorganismen und Zellkulturen, DSMZ). In 1970 this cell line was established 
from the pleural effusion of a 53-year-old woman with CML 149. The cells bear the 
Philadelphia chromosome and show spontaneous and inducible globin gene expression 
150.  
• The HEL cell line (DSMZ). It was established in 1980 from a 30-year-old man who 
suffered from erythroleukemia, a form of acute myeloid leukemia (AML), which is 
classified as acute nonlymphocytic leukemia of the M6 type. These cells were described 
to differentiate spontaneously towards the erythroid pathway 150. 
• The TF-1 cell line (DSMZ). In 1987 this cell line was established from the bone 
marrow of a 35-year-old man with erythroleukemia (AML M6) 151,152. The cells are 
proliferatively responsive to several hematopoietic growth factors including Epo, 
granulocyte-macrophage colony stimulating factor (GM-CSF), interferon gamma 
(IFNγ), Interleukin 3 (IL-3), IL-4, IL-5, IL-6, TNF-α, and others.  
4.2.1.1 Freezing and thawing of the stocks 
Cell stock aliquots are deep-freezed in a RPMI solution containing 20% fetal calf serum 
(FCS) and 10% dimethyl sulfoxide (DMSO). They are stored in liquid nitrogen. The 
thawing is done by heating the cells rapidly to 37 °C and putting them in their usual cell 
culture conditions (see maintenance of the cell culture). The number of cell passages is 
restricted to 30 before thawing a new cell stock.  
4.2.1.2 Maintenance of the culture 
K562 and HEL cells are grown in RPMI 1640 Medium supplemented with 10% of FCS 
and 1% of a mixture of antibiotics (penicillin 100 U/mL, streptomycin 100 µg/mL) and 
an antifungal agent (amphotericin B, 25 µg/mL).  
TF-1 cells are cultured in RPMI 1640 Medium supplemented with 20% of FCS and 1% 
of a mixture of antibiotics (penicillin 100 U/mL, streptomycin 100 µg/mL) and an 
antifungal agent (amphotericin B, 25 µg/mL) as well as 5 ng/mL of GM-CSF. Before 
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treating the TF-1 cells with Epo, GM-CSF is discarded overnight (O/N). Cells cultured 
with GM-CSF were used as controls (C). 
Cells are routinely cultured in an incubator at 37 °C with 95% humidity and 5% CO2. 
Every 3 days, the cells are subcultured and seeded at a concentration of 200.000 cells 
per mL. Cell counts were performed with a Malassez chamber using Trypan Blue 
exclusion method. 
4.2.2 Magnetic cell sorting of CD34+ cells from umbilical cord blood 
Umbilical cord blood samples were collected from healthy donors after informed 
consent under protocols approved by the Bohler Hospital Ethics committee. The cord 
blood is collected in 50 mL tubes containing an anticoagulant (20 U/mL Heparin in 5 
mL phosphate buffered saline (PBS), and then diluted 1:4 with PBS containing 2 mM 
ethylene-diamin-tetra-acetat (EDTA) within 4 hours. The diluted cell suspension (35 
mL) is then carefully layered of over 15 mL of Ficoll-Paque Premium. The mononuclear 
cells are isolated by centrifugation (35 min, 400 g, 20 °C) in a swinging-bucket rotor 
without brake. Interphase cells are carefully collected and washed twice with 50 mL 
PBS containing 2 mM EDTA. Cells are centrifuged 10 min at 200 g at 20 °C. Cell 
counts are performed with a Malassez chamber using Trypan Blue exclusion method. 
The cell pellet is then resuspended in a final volume of 300 µL magnetic cell sorting 
(MACS) buffer/108 cells (MACS buffer: PBS pH7.2, supplemented with 0.5% bovine 
serum albumin (BSA) and 2 mM EDTA).  
MACS of CD34+ cells is performed using the MidiMACS manufacturer’s protocol. The 
purity of the eluted CD34+ cells, resuspended in 60 µL MACS buffer (MACS buffer: 
PBS pH 7.2, supplemented with 0.5% BSA and 2 mM EDTA) is then analyzed by 
FACS calibur using 3 µL fluorescein isothiocyanate (FITC) conjugated anti-CD34, as 
well as 3 µL peridinin chlorophyll A protein (PerCP) conjugated anti-CD45. The 
suspensions were incubated for 10 min on ice in the dark and then washed by adding 1 
mL PBS. The cells were processed in the flow cytometer. Statistics were elaborated in 
50000 events/sample by WinMDI software.  
4.2.2.1 CD34+ cell culture 
The CD34+cells were cultured in serum-free liquid medium, supplemented with 10 
U/mL penicillin/streptomycin and a cocktail of cytokines as follows: days 0–3, 10 
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ng/mL IL-3 and 10 ng/mL SCF; days 3–7, 10 ng/mL IL-3, 10 ng/mL SCF, and 2 U/mL 
EPO; days 7–9, 10 ng/mL SCF and 2 U/mL EPO; and after day 9, 2 U/mL EPO 153. 
4.2.3 Viability assay 
Trypan Blue is a vital dye. This chromophore is negatively charged and therefore not 
able to interact with the cell membrane unless the cell is damaged. Viable cells remain 
unstained, while non-viable cells are stained blue. The ratio gives the percent of viability 
for each coverslip.  
4.2.4 Exponential growth phase 
Before any treatment, the cells are seeded at 200.000 cells/mL. After 24 hours (h), at the 
beginning of the exponential growth phase, the cells are recounted to have a 
concentration of 200.000 cells/mL at the moment of treatment. 
4.3 Erythroid differentiation inducers, TNFα and inhibitors 
4.3.1 Erythroid differentiation inducers 
Different pharmacologic agents were used as erythroid differentiation inducers. They 
are known to induce the erythroid differentiation pathway by different, not fully 
understood mechanisms.  
All solution preparations and treatments were done under sterile conditions. Preparation 
as well as dilutions steps of Hemin (He), Aclacynomicin A (Acla) and Doxorubicin 
(Dox) were done in the dark. 
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4.3.1.1 Aclacynomicin A 
 
Figure 4: Chemical structure of Aclacynomicin A 
Aclacynomicin A (Acla) is a cytotoxic anthracycline used as anticancer agent isolated 
from Streptomyces galilaeus 154. This cell-permeable agent acts as a catalytic inhibitor 
of topoisomerase I/II 155 and of the degradation of ubiquitinilated proteins 156. Acla stock 
solution (10-3 M) is prepared by dissolving 5 mg of Acla (molecular weight (MW): 812 
g/mol) powder in 6.2 mL DMSO. Aliquots are stored at -20 °C. The treatment solutions 
are diluted using RPMI culture medium.  
4.3.1.2 Doxorubicin 
 
 
Figure 5: Chemical structure of Doxorubicin Hydrochloride  
Doxorubicin (Dox) is a cytotoxic anthracycline antibiotic isolated from Streptomyces 
peucetius var. caesius 157. It is used alone or in combination with other drugs as 
treatment against a wide range of cancers including solid tumors, leukemias, and 
lymphomas 158. The exact mechanism of this antineoplastic agent remains unknown but 
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it may involve inhibition of the nuclear enzyme DNA topoisomerase II 159,160 inducing 
double-strand DNA breakage 161,162, and generation of superoxide, hydrogen peroxide 
and hydroxyl radicals 163. The stock solution (10-3 M) is prepared by dissolving 5 mg of 
Dox (MW: 812 g/mol) powder in 8.6 mL sterile water. Aliquots are stored at -20 °C. 
The treatment solutions are diluted in RPMI culture medium.  
4.3.1.3 Hemin 
 
Figure 6: Chemical structure of Hemin  
Hemin (He) or Ferriprotoporphyrin IX is a porphyrine. To prepare the He stock solution 
(10-3 M), 65.2 mg (MW: 652 g/mol) are dissolved in 2.5 mL absolute ethanol added to 
2.5 mL KOH 0.2 M. After addition of 95 mL PBS 1X [from a solution PBS 10X (pH 
7.4, 1.4 M NaCl, 27 mM KCl, 15 mM KH2PO4, 65 mM Na2HPO4] dissolved in H2O), 
the solution is filtered (0.22 µm) and aliquots are stored at -20 °C. The treatment 
solutions are diluted in RPMI culture medium.  
4.3.1.4 Erythropoietin  
Erythropoietin (Epo) is a 30.4 kDa glycoprotein growth factor produced primarily in the 
adult kidney under the control of an oxygene-senitive mechanism that triggers 
erythrocyte production 164. Epo regulates the red blood cell production in the bone 
marrow to sustain the oxygen – bearing capacity of the peripheral blood under 
physiologic conditions 165. The local oxygen tensions are controlled by HIF 166. HIF 
cannot be hydroxylated under hypoxia conditions, is therefore stabilized and thus 
upregulates Epo production 167. Recombinant Epo has been widely used in the clinic to 
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prevent or treat malignancy-associated anemia 168. Epo stock solution (10000U/mL) was 
diluted to 10 U/mL (TF-1 cells) or 2 U/mL (CD34+ cells) in RPMI culture medium. 
4.3.2 TNFα 
TNFα stock solution (10 µg/mL) is prepared by dissolving 10 µg of TNFα (T) in 1 mL 
of PBS 1X (from a PBS 10X solution (pH 7.4, 1.4 M NaCl, 27 mM KCl, 15 mM 
KH2PO4, 65 mM Na2HPO4) dissolved in H2O) supplemented with 0.5% BSA and stored 
at 4 °C. The treatment solutions are diluted in RPMI culture medium. 20 ng/mL T were 
added to cell suspension as a pretreatment for 1 hour prior to the addition of 
differentiating inducers. 
4.3.3 Inhibitors 
These inhibitors have to be protected from light and are given to the cells one hour prior 
to TNFα or any inducer treatment. 
4.3.3.1 Remicade 
Remicade (R) (generic name: Infliximab) is an IgG1 monoclonal anti-TNFα antibody 
composed of human constant and murine variable regions. It is used to eliminate the 
excess of TNFα from the circulation and from the sites of inflammation in various 
diseases such as Crohn’s disease, rheumatoid arthritis, psoriasis, and ankylosing 
spondylitis 169-178. The stock solution, which is also used for patients’ treatment, has a 
concentration of 100 mg/10 mL H2O. The treatment solutions are diluted to a 
concentration of 100 µg/mL in RPMI culture medium.  
4.3.3.2 Lactacystin 
Lactacystin is an organic compound naturally synthesized by bacteria (Streptomyces) 
that is widely used as a selective inhibitor of the 20 S proteasome 179,180. For a stock 
solution of 13.35 mM lactacystin, 2 mg lactacystin were dissolved in 398 µL sterile H20. 
The treatment solutions are diluted to a concentration of 1 µM lactacystin in RPMI 
culture medium. 
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4.3.3.3 Bay11-7082 
Bay11-7082: an inhibitor of NF-κB activation, which prevents a step of the 
phosphorylation of inhibitory protein IκBα bound to NF-κB. Bay11-7082  stock solution 
(10 mM) was diluted to 1 µM in RPMI culture medium. 
4.3.3.4 U0126 
U0126 is a chemically synthesized organic compound, which inhibits both active and 
inactive MAPK kinase (MEK) thus blocks the ERK pathway. It has a 100-fold higher 
potency than PD98059. The stock solution (20 mM in DMSO) is diluted to a 
concentration of 10 µM in RPMI culture medium. 
4.3.3.5 PD98059 
PD98059 is a potent MAPK kinase inhibitor, which only inhibits activation of inactive 
MEK. PD98059 does not inhibit MAPK itself. The stock solution (20 mM in DMSO) is 
diluted to a concentration of 10 µM RPMI culture medium. 
4.3.3.6 SB203580 
SB203580 is a highly selective inhibitor of p38. It binds within the ATP pocket of the 
active kinase. SB203580 selectively inhibits the p38α and β isoforms. SB203580 stock 
solution (10 mM in DMSO) was diluted to 10 µM µM in RPMI culture medium. 
4.3.3.7 SP600125 
SP600125 is a selective JNK inhibitor. It competitively and reversibly inhibits JNK1, 2 
and 3. SP600125 stock solution (10 mM in DMSO) was diluted to 10 µM µM in RPMI 
culture medium. 
4.3.3.8 Ly294002 
Ly294002 is a selective phosphatidylinositol 3-kinase (PI3K) inhibitor. Ly294002 
blocks the catalytic activity of PI3K. Ly294002 stock solution (10 mM in DMSO) was 
diluted to 10 µM µM in RPMI culture medium. 
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4.4 Benzidine staining 
The benzidine reagent is used to identify Hemoglobin-containing cells, as described 
previously 181,182. It forms a blue precipitate upon oxidation by the heme group of 
hemoglobin in the presence of hydrogen peroxide (H2O2). Therefore it serves as a 
histochemical stain specific for differentiated red blood cells.  
 
Phosphate Buffered Saline (PBS) 10X 
(pH 7.4) 
1.4 M NaCl, 27 mM KCl, 15 mM 
KH2PO4, 65 mM Na2HPO4 
PBS 1X 1:10 dilution of PBS 10X in H2O 
NaCl (0.9%) 1.54 mL 1M NaCl, ad 10 mL H2O 
benzidine chlorhydrate solution 
0.2 g benzidine chlorhydrate, 2.85 mL 
acetic acid, ad 100 mL H2O (in the 
dark)   
H2O2  
 
 spin 3x105 cells down [5 minutes (min) at room temperature, 600 rcf (relative 
centrifugal force, g)]  
 rinse the cells with 1 mL PBS 1X 
 spin cells down (5 min, 600 rcf) 
 carefully pour off the supernatant 
 mix 1 mL benzidine solution with 20 µL H2O2 in a separate tube 
 resuspend the cell pellet with 100 µL NaCl (0.9%) and 50 µL benzidine/H2O2 
 leave 20 minutes in the dark 
 add 300 µL NaCl (0.9%) 
 observe and count the percentage of differentiated (blue) cells using the microscope 
4.5 Total RNA extraction  
The extraction is realized from 107 cells by using the TRIzol reagent. This is a 
monophasic solution of phenol and guanidine isothiocyanate for isolating total RNA. In 
fact this reagent is lysing the cells. Adding chloroform separates the organic and 
aqueous phases. Phenol removes the proteins from nucleic acid samples during 
isolation.  
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TRIzol  
1-Bromo-3-Chloro-Propane  
Isopropanol  
Ethanol (75%)  
H2O DEPC (diethylpyrocarbonate)  
 
 spin 107 cells down (5 min, 600 rcf)  
 wash the cell pellet with PBS 1X 
 spin cells down (5 min, 600 rcf) 
 homogenize by adding 1 mL TRIzol, hold 5 min at room temperature 
 add 200 µL 1-Bromo-3-Chloro-Propane, vortex for 15 sec until the emulsion turns to 
pale rose 
 incubate for 5 min at room temperature  
 centrifuge (15 min, 12000 rcf, 4 °C) 
 remove the colorless upper phase containing the RNA in a separate tube 
 add 500 µL Isopropanol and incubate for 10 min at -20 °C or O/N at 4 °C  
 centrifuge (10 min, 12000 rcf, 4 °C) 
 recover the translucent pellet by removing the supernatant 
 wash the pellet by adding 1 mL Ethanol 75% 
 centrifuge (5 min 30 sec, 11000 rcf, 4 °C) 
 recover the translucent pellet by removing the supernatant 
 dry the pellet for 5-10 min 
 add 50-100 µL H2O DEPC depending on the size of the pellet 
 put the tubes for 5 min in the water bath at 55 °C  
 for quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) 
analysis, RNA was cleaned using RNeasy Mini Kit from Quiagen, and RNA integrity 
and purity was controlled using a Bioanalyzer (Agilent). 
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 quantify the RNA by measuring the optical density (OD) 260 nm using the Nanodrop 
ND1000, considering the dilution and multiplying by 40 (1 OD 260 = unit of single 
stranded RNA = 40 ug) 
4.6 PCR analysis 
The polymerase chain reaction (PCR) is a technique that amplifies a DNA template to 
produce specific DNA fragments in vitro. The PCR method was initially developed to 
amplify segments of a longer DNA molecule 183,184. The amplification includes the 
target DNA, a thermostable DNA polymerase, two oligonucleotide primers, 
deoxynucleotide triphosphates (dNTPs), reaction buffer and magnesium. Each cycle of 
PCR includes steps for template denaturation, primer annealing and primer extension.  
4.6.1 Reverse transcription (RT)-PCR 
In order to apply PCR to the study of RNA, the RNA sample must first be reverse 
transcribed to cDNA to provide the necessary DNA template for the thermostable 
polymerase. This process is called reverse transcription (RT). The RT-PCR is realized 
with substances from Invitrogen. 
10 mM dNTP mix  
Oligo(dT) primers  
10X RT buffer  
25 mM MgCl2  
0.1 M DTT 1 (1,4-Dithiothreitol)  
RNaseOUT  
Superscript II RT  
RNase H  
10X PCR buffer  
50 mM MgSO4  
Platinum Taq polymerase  
H2O DEPC  
TBE 10X 
0.9 M Trishydroxymethylaminomethane 
(TRIS) base, 0.9 M boric acid, 25 mM EDTA 
(pH 8.0) ad 1l H2O  
loading buffer Glycerol 33%, TBE 2X, Bromophenol Blue 0.005%, Xylene cyanole 0.005% 
Gel 2% agarose 2%, TBE 1X, 2% ethidium bromide  
GATA-1 (s) : 5’-TCAATTCAGCAGCCTATTCC-3’  
(as) :5’-TTCGAGTCTGAATACCATCC-3’ 
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GATA-2 (s) : 5’-TGTTGTGCAAATTGTCAGACG-3’ 
(as) : 5’-CATAGGTGCCATGTGTCCAGC-3’ 
γ-globine (s) : 5’-GGCAACCTGTCCTCTGCCTC-3’ 
(as) : 5’-GCCAGGAAGCCTGCACCTCA-3’ 
EpoR (s) : 5’-GGTCCTCCGTGAAGGGGGTGC-3’ 
(as) : 5’-AGCCTGTGTCGCTGCTGACGC-3’ 
S14 (s) : 5’-GGCAGACCGAGATGAATCCTC-3’ 
(as) : 5’-CAGGTCCAGGGGTCTTGGTCC-3’ 
 put RNA samples for 8 min in the water bath at 65 °C  
 centrifuge and put on ice  
 mix following reagents in an 0.5 mL tube: 
- 5 µg RNA 
- 1 µL 10 mM dNTP mix 
- 1 µL Oligo(dT) (0.5 µg/µL) 
- ad 10 µL H20 DEPC 
 
 incubate for 5 min at 65 °C  
 put on ice for at least 1 min 
 add 9 µL MIX: 
- 2 µL 10X RT buffer 
- 4 µL 25 mM MgCl2 
- 2 µL 0.1 M DTT 
- 1 µL RNaseOUT 
 incubate at 42 °C for 2 min 
 add 1 µL Superscript II RT (50 U) 
 incubate at 42 °C for 50 min 
 incubate at 70 °C for 15 min 
 add 1 µL RNase H 
 incubate at 37 °C for 20 min 
 store at -20 °C 
Then the PCR is performed:  
 in an 0.2 mL tube mix following reagents: 
- 10X PCR buffer  
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- 2 - 3 µL 50 mM MgCl2 
- 1 µL 10 mM dNTP mix 
- 1 µL sense (s) primer 
- 1 µL antisense (as) primer 
- 0.2 µL Platinum Taq (5 U/µL) 
- 2 µL cDNA 
- ad 50 µL DEPC H2O 
 
 The following program is performed: 
 
- 5 min at 94 °C  initial denaturation 
- 2 min at 94 °C  denaturation         
- 1 min at 60 °C  primer-hybridization       x cycles depending on the primers used 
- 2 min at 68 °C  polymerization 
- 2 min at 68 °C  final extension 
- hold at 4 °C 
 
 
primers number of cycles (x) 
S14 20 
GATA-1 22 
γ-globin 20 
EpoR 26 
 
 run a 2% agarose gel 
 add 6 µL loading buffer to the samples and run the gel 
 take a photo under UV-light, and quantify the bands using the quantification progam 
Kodak 1D 3.5 and compare these results with the ones obtained with the reference gene 
S14 (40S ribosomal protein). 
4.6.2 Quantitative real-time PCR (qRT-PCR) 
1.5 µg of total RNA were used to perform cDNA synthesis using RT2 PCR Array First 
Strand Kit (C-02) (SuperArray) according to the manufacturer’s instructions. qRT-PCR 
was performed with SuperArray primers according to manufacturers using a custom 
RT2 Profiler PCR Array System (table 1) using a 7300 real-time PCR System (Applied 
Biosystems). Results were evaluated using an Excel-based data analysis template from 
SuperArray.  
    
  
Materials and Methods 
32 
Table 1: Genes used for custom RT2 Profiler PCR Array System 
 
4.7 Nuclear and cytoplasmic protein extraction 
Nuclear and cytoplasmic proteins are extracted from 107 cells with or without treatment 
using the method described by Schreiber et al. 185. During this procedure the cell 
membranes are lysed in a hypertonic detergent medium containing protease inhibitors. 
The extraction is realized on ice to avoid denaturation of the proteins.     
 
PBS 10X (pH 7.4) 1.4 M NaCl, 27 mM KCl, 15 mM KH2PO4, 65 mM Na2HPO4 
buffer A 
Hepes (pH 7.9) 10 mM, KCl 10 mM,  EDTA 0.1 mM, EGTA 0.1 mM, 
DTT 1 mM, PMSF 0.5 mM, 0-Phenylanthroline 1 mM, Aprotinine 2 
µg/mL, Leupeptine 30 µg/mL, Pepstatine 15µg/mL 
buffer B 
Hepes (pH 7.9) 20 mM, NaCl 0.4 mM,  EDTA 1 mM, EGTA 1 mM, 
DTT 1 mM, PMSF 1 mM, 0-Phenylanthroline 1 mM, Aprotinine 2 
µg/mL, Leupeptine 30 µg/mL, Pepstatine 15 µg/mL, Glycerol 20% 
Igepal 10%  
BSA 20 µg/mL 
Bradford solution  
 
 spin 107 cells down (5 min, 600 rcf)  
 wash the cell pellet with PBS 1X 
 spin cells down (5 min, 600 rcf)  
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 resuspended the pellet with 400 µL buffer A, keep on ice for 15 min 
 add 25 µL Igepal 10%  
 vortex during 10 seconds (sec) 
 centrifugate (30 sec, 15700 rcf, 4 °C) 
 transfer the supernatant with the cytoplasmic proteins is in a second tube 
 resuspend the pellet containing the nuclei in 50 µL buffer B 
 vortex the solution horizontally for 15 min at 4 °C 
 pool the supernatants and divide them  in aliquots of 10 µL (4 °C) 
 quantify the protein concentration by establishing a BSA reference curve according to 
Bradford 186. 
 
4.8 Western Blot 
For western blot analysis a sodium dodecyl sulfate-polyacrylamide electrophoresis 
(SDS-PAGE) is realized to separate the proteins by size, which are transferred from the 
gel to a PVDF membrane via electro transfer. Finally, this blot is processed for the 
detection of specific proteins with a primary antibody (ab), detected by a 
chemifluorescent secondary ab. 
 
denaturation & loading buffer (2X) Tris-HCl (pH 6.8) 0.125 M, Glycerol 20%, SDS 4%, bromophenol blue 0.005%, 2-Mercaptoethanol 5% 
electrophoresis buffer (10X)  Tris 30 g, Glycine 144 g, SDS 10 g → ad 1 l H2O 
concentration gel (4%) liquid gel (37.5:1) 4%, Tris-HCl (pH 6.8) 0.125 M, SDS 0.1%, ammonium persulfade 0.1%, Temed 0.05%   
separation gel (10%) liquid gel (37.5:1) 10%, Tris-HCl (pH 8.8) 0.375 M, SDS 0.1%, ammonium persulfade 0.1%, Temed 0.05%   
transfer buffer (1X) Tris 3 g, Glycine 14.4 g, Methanol 50 mL → ad 1 l H2O 
PBS 10X (pH 7.4) 1.4 M NaCl, 27 mM KCl, 15 mM KH2PO4, 65 mM Na2HPO4 
PBS-T PBS 10X 100 mL, 1 mL Tween 20 → ad 1 l H2O 
BSA  
milk  
antibody anti-acetyl-Lysine 
monoclonal mouse IgG 1:500 in PBS-T-milk 5% 
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antibody anti-GATA-1 N-1 rat 
monoclonal IgG (200 µg/0.1 mL) 1:5000 in PBS-T-BSA 5% 
antibody anti-GATA-1 C-20 goat 
polyclonal IgG (200 µg/0.1 mL) 1:5000 in PBS-T-BSA 5% 
antibody anti-GATA-2 goat 
polyclonal IgG (200 µg/mL) 1:8000 in PBS-T-milk 5% 
antibody anti-EpoR M-20 rabbit 
polyclonal IgG (200 µg/mL) 1:1000 in PBS-T-milk 5% 
antibody anti-β-actin mouse 
monoclonal IgG (200 µg/0.1 mL) 
1:5000 in PBS-T-milk 5%  
antibody anti-FOG-1 goat polyclonal 
IgG M-20 1:500 in PBS-T-milk 5% 
antibody anti-γ-globin mouse 
monoclonal IgG (51-7) 1:8000 in PBS-T-milk 5% 
antibody anti-phospho-p38 rabbit 
polyclonal IgG 1:1000 in PBS-T-BSA 5% 
antibody anti-p38 rabbit polyclonal 
IgG 1:1000 in PBS-T-BSA 5% 
antibody anti-PU.1 rabbit polyclonal 
IgG (Spi-1, T-21) 1:500 in PBS-T-milk 5% 
goat anti-mouse IgG-HRP conjugated 
(200 µg/0.5 mL) 1:10000 in PBS-T-milk 5%  
goat anti-rat IgG-HRP conjugated 
(200 µg/0.5 mL) 1:5000 in PBS-T-milk 5%  
donkey anti-goat IgG-HRP 
conjugated (200 µg/0.5 mL)  1:3000 in PBS-T-milk 5% 
donkey anti-goat IgG-HRP 
conjugated (200 µg/0.5 mL)   1:4000 in PBS-T-milk 5% 
donkey anti-goat IgG-HRP 
conjugated (200 µg/0.5 mL)  1:5000 in PBS-T-milk 5% 
donkey anti-rabbit IgG-HRP 
conjugated (200 µg/0.5 mL) 1:5000 in PBS-T-milk 5% 
Ecl + Lumigen PS-3 detection reagent  
 
 add the volume of 5-20 µg proteins to an equal volume of  denaturation & loading 
buffer (2X)  
 incubate in the water bath for 5 min at 100 °C  
 put on ice 
 centrifuge (5 sec, 1900 rcf) and put the samples on the SDS-PAGE 
 migrate at 10 mA/gel in the concentration gel and at 20 mA/gel in the separation gel 
using electrophoresis buffer (1X) 
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 after separation, transfer the proteins on a PVDF membrane at 100 mA/gel using 
transfer buffer 1X  
 saturate the membrane either in PBS-T-milk 5% during the night at 4 °C or in BSA 
during 1 hour at room temperature depending on the primary antibody ab used 
 wash the membrane 2 x 5 min, 1 x 10 min with PBS-T 
 incubate the membrane with the first ab for 1 h at room temperature or O/N at 4 °C 
depending on the primary ab used 
  wash the membrane 2 x 5 min, 1 x 10 min with PBS-T 
 incubate the membrane with the secondary ab for 1 h at room temperature 
 wash the membrane 2 x 5 min, 1 x 10 min with PBS-T 
 visualize the protein using the chemiluminescent Ecl-detection reagent, the photo film 
and the development solutions and machinery 
4.9 Flow cytometry analysis 
The expression of GPA of differentiated cells is analyzed by using flow cytometry 
analysis. Glycophorins are sialoglycoproteins of the human erythrocyte membrane, 
which bear the antigenic determinants. The genetic array of expressed glycophorin 
surface antigens on erythrocytes defines the blood group phenotype of the individual.  
 
PBS 10X 1.4 M NaCl, 27 mM KCl, 15 mM KH2PO4, 65 mM Na2HPO4 
Cytofix/Cytoperm  
Perm/Wash buffer  
antibody anti-GPA goat 
polyclonal IgG E-18   1:50 in Perm/Wash buffer 
Alexa Fluor® 488 donkey 
anti-goat IgG (H+L) 1:200 in Perm/Wash buffer 
 
 spin  10*106 cells down (350 rcf, 7 min)  
 rinse the cells with 1 mL PBS 1X, centrifuge (450 rcf, 7 min) 
 discard supernatant  
 add 250 µL Cytofix/Cytoperm 
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 incubate for 20 min at 4 °C 
 rinse the cells with 1 mL Perm/Wash buffer solution 1X, centrifuge (450 rcf, 7 min) 
 incubate the cell pellet with 60 µL GPA ab solution for 1 h shaking  
 rinse the cells with 1 mL Perm/Wash buffer solution 1X, centrifuge (450 rcf, 7 min) 
 incubate the cell pellet with 60 µL secondary ab (488 donkey anti-goat IgG) for 30 
min shaking in the dark 
 rinse the cells with 1 mL Perm/Wash buffer solution 1X, centrifuge (450 rcf, 7 min) 
 add 5 mL PBS  
 Cells are then processed in a FACS calibur flow cytometer. Statistics were elaborated 
in 50000 events/sample by WinMDI software. 
4.10 Immunoprecipitation 
Protein-protein interactions between GATA-1 and FOG-1, and acetylated GATA-1 
were determined by immunoprecipitation (IP) experiments based on the protocol of 
Ribeil and coworkers 187.  
lysis buffer 
Igepal 1%, 150 mM NaCl, 5 mM EDTA, 65 mM TrisHCl pH 8, 50 
mM Hepes, 3% glycerol, 1 mM orthovanadate, 1 mM PMSF, 1 mM 
DTT, 40 µg/mL complete 
low salt buffer 20 mM Tris HCl pH 7.5 
elution buffer 50 mM TrisHCl pH 6.8, 50 mM DTT, 1% SDS, 0.005% bromphenolblue, 10% glycerol 
PBS 10X 1.4 M NaCl, 27 mM KCl, 15 mM KH2PO4, 65 mM Na2HPO4 
2 µg anti-GATA-1 ab (sc-
1233X)  
 
 spin  10*106 cells down (350 rcf, 7 min)  
 rinse the cells with 10 mL PBS 1X, centrifuge (450 rcf, 7 min) 
 discard supernatant  
 add 1 mL lysis buffer, mix vigorously for 20 min 
 centrifuge (30 min, 15700 rcf, 4 °C) 
 preheat heating block (95 °C) 
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  whole cell lysates (500 µg) were diluted 1:3 in H2O and incubated on ice for 1.5 hours 
with 2 µg anti-GATA-1 ab (sc-1233X) in the presence of 100 µL Protein G Microbeads 
(Miltenyi) 
 place µColumn in magnetic field 
 rinse column with 200 µL lysis buffer 
 place elution buffer (90 µL) in preheated block 
 immune complex was immobilized to the µColumn  
 rinse 4x with 200 µL lysis buffer 
 rinse with 200 µL low salt buffer 
 apply 20 µL of preheated (95 °C) elution buffer 
 incubate for 5 min 
 place a new tube under the column 
 apply 50 µL of preheated (95 °C) elution buffer 
 perform immunoblotting (see section 3.9) using the GATA-1 (sc-266X), FOG-1 (sc-
9361), and acetyl-Lysine (4G12) antibodies. 
4.11 Electrophoretic Mobility Shift assay (EMSA)  
EMSA is a technique for studying DNA-protein interactions in vitro. Double stranded 
oligonucleotides are used to examine binding affinity of cell extracts for specific DNA 
elements. Nuclear extracts are incubated with a radioactively labeled probe, which 
contains the specific recognition sequence for NF-κB or GATA. The binding occurs 
under precise salt and pH settings in a binding buffer. Poly-dIdC is used to prevent 
unspecific binding of proteins to the probe and thus reduce background. After binding, 
the samples are separated on a non-denaturating gel, DNA-protein complexes migrate 
more slowly than the unbound radioactive probe and consequently they are visualized as 
distinct bands of radioactivity on an acrylamide gel image detected by autoradiography.  
In order to determine which proteins are responsible for the observed bands, a 
"supershift" can be realized by adding specific antibodies to the binding reactions. The 
antibodies will bind to the corresponding protein, leading to a protein-probe-ab ternary 
complex. Consequently the electrophoretic mobility of this complex is lower than that of 
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the protein-probe complex so that a supershifted band can be observed. Occasionally an 
ab does not result in a shifted band even if its corresponding subunit is present: instead, 
by binding to its subunit, the ab prevents the association of the subunit and the labeled 
probe so that the intensity of the primary shifted signal decreases. In this case, we talk 
about immunodepletion. 
 
TBE 10X 0.9 M TRIS base, 0.9 M boric acid, 25 mM EDTA (pH 8.0) ad 1l H2O  
GATA consensus  (s) :5’-GGCAGTGCCTTATCTCTGCGGCG-3’ 
(as) :5’-CGCCGCAGAGATAAGGCACTGCC-3’ 
NF-κB consensus  
(s) : 5’-AGTTGAGGGGACTTTCCCAGGC-3’ 
(as) : 5’-GCCTGGGAAAGTCCCCTCAACT-3’ 
binding buffer  5X (hybridization) Tris (pH 7.5) 335 mM, MgCl2 65 mM, DTT 33 mM, EDTA 6.5 mM 
ethanol (100%)  
T4 Polynucleotide kinase & kinase buffer 10X  
Poly-dIdC  
gamma-32P-phosphate 7000 Ci/mmol 
Qiaquick Removal Nucleotide kit  
binding H2O (+ protease-inhibitors) 
DTT 0.5 mM, PMSF 0.5 mM, Aprotinine 1 µg/mL, 
O-phenanthroline 1 mM, Leupeptine 30 µg/mL 
binding buffer 5X (MIX) Tris-HCl (pH 8.0) 10 mM, NaCl 50 mM, EDTA (pH 8) 1 mM, Glycerol 5%, DTT 1 mM, PMSF 2.5 mM 
BSA 2 mg/mL 
Spermidine 80 mg/mL 
antibody anti-GATA-1 rat monoclonal IgG 
(200 µg/100 µL) 2 µg 
antibody anti-GATA-2 goat polyclonal IgG 
(200 µg/100 µL) 2 µg 
NF-κB p50 rabbit polyclonal IgG (200 µg/100 
µL) 2 µg 
NF-κB p65 rabbit polyclonal IgG (200 µg/100 
µL) 2 µg 
loading buffer Glycerol 33%, TBE 2X, Bromophenol Blue 0.005%, Xylene cyanole 0.005% 
polyacrylamide gel (29 :1) 5% TBE 0.5X, ammonium persulfate 0.2%, Temed 0.1% 
 
4.11.1 Hybridization and labeling of the oligonucleotide probe  
In a PCR tube (0.5 mL), add following components: 
- 1500 ng oligonucleotide sense 
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- 1500 ng oligonucleotide antisense 
- 12 µL binding buffer 5X 
- ad 60 µL H2O MilliQ  
 
The hybridization is realized at the following temperatures: 
- 90 °C during 5 min 
- 65 °C during 10 min 
- 37 °C during 10 min 
- 20 °C during 10 min 
- 4 °C until the precipitation of the probe 
 
After hybridization, transfer the double-stranded probe in a 1.5 mL tube: 
 add 3X volume 100% ethanol and 0.1 volume Natrium acetate 
 incubate for 1 h on ice (4 °C)  
 centrifuge (5 min, 15700 rcf, 4 °C) 
 wash the pellet with 200 µL ethanol 75% 
 centrifuge (5 min, 15700 rcf, 4 °C) 
 dry the pellet using the Speedvac (5-10 min) 
 resuspend the pellet with 15 µL H2O MilliQ 
 store at – 20 °C 
The probe labeling is realized by using the T4 Polynucleotide kinase which catalyzes the 
transfer of the gamma-32P-phosphate from ATP to the 5'-OH group of DNA and RNA 
188-190. 
The labeling is realized in the following mixture: 
- 2 µL double stranded oligonucleotide 
- 2 µL γ-32P-phosphate ATP  
- 1 µL T4 Polynucleotide kinase 
- 2 µL kinase buffer 10X 
- 13 µL H2O 
 
 incubate for 30 min at 37 °C 
 purify the probe using the kit “Qiaquick Removal Nucleotide” 
 elute with 35 µL H2O 
 store the labeled probes in a lead chest at -80 °C 
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4.11.2 protocol 
 Assemble plates, spacers, clamps  
 run the 5% polyacrylamide gel 
 incubate 10 µg nuclear extracts with the following MIX:  
- 0.25 µL radioactive probe 
- 7 µL binding H2O 
- 2.5 µL binding buffer (MIX) 
- 2.5 µL Poly dIdC 
- 2 µL BSA (2 mg/mL) 
- 1 µL Spermidine (80 mg/mL) 
 
 [incubate for 30 min at 4 °C with 2 µg of specific ab (anti-p50, anti-p65 for the NF-κB 
subunits, anti-GATA-1, anti-GATA-2) before adding the radioactive probe to realize a 
supershift] 
 incubate for 20 (GATA1/-2) and 45 (p50, p65) min on ice (4 °C) 
 add 6 µL loading buffer 
 put the whole MIX on the gel 
 run the gel (3 h, 16 mA/gel) 
 dry the gel  
 results are analyzed using an autoradiography or the PhosphorImager (Cyclone 
OptiQuant) 
 
4.12 TransAM 
TransAM assays were performed according to the manufacturer’s instructions (Active 
Motif, Belgium). The GATA-1 binding assay consists of a multiwell plate coated with 
DNA trappers containing the GATA-1 motif. These kits contain a 96-stripwell plate to 
which the consensus binding site oligonucleotide has been immobilized. Activated 
nuclear extract is added to each well and the transcription factor of interest binds 
specifically to the oligonucleotide. A primary ab specific for an epitope of the 
transcription factor is then added followed by incubation with a secondary ab and 
Developing Solution to provide a quantified and colorimetric readout at 450 nm with a 
reference wavelength of 655 nm. 
    
  
Materials and Methods 
41 
4.13 Plasmids and transient transfection assays 
4.13.1 Recombinant vectors used 
 expression plasmid: pXM-GATA-1, containing the gene which encodes the 
protein GATA-1 (gift from L. Collavin).  
 reporter plasmid: pGL3-GATA-luc, in this plasmid the luciferase gene is 
associated to three consensus GATA binding sites under the control of the 
minimal metallothionein promoter in the basic pGL3-vector 30. 
4.13.2 Bacteria transformation and purification of plasmids 
The aim of this procedure is to amplify plasmid DNA. This step is necessary to prepare 
a sufficient quantity of vectors for the transfection experiments. All experiments were 
realized under sterile conditions and following standard protocols.  
LB Broth, Miller 25 g ad 1 l H2O, autoclaved  
LB Agar, Miller 32 g  ad 1 l H2O, autoclaved 
ampicillin 100 µg/mL dissolved in H2O 
TOP 10F’ one shot bacteria  
 
 cool down autoclaved LB Agar to 40-50 °C  
 add 100 µg/mL ampicillin and mix gently 
 pour LB Agar into petri dishes using sterile technique 
 allow to solidify  
 store the petri dishes upside down at 4 °C until use (stable for 4 weeks covered by 
aluminum foil) 
 200 µL competent bacteria  (TOP 10F’ one shot) are incubated with 5 ng recombinant 
plasmid during 15 min at 4 °C 
 apply a heat shock to this mixture (45 sec at 42 °C) 
 put on ice (4 °C) 
 sterilely place the transformed cells on the agar surface and spread it out uniformly 
over the entire surface with a sterile pipette tip 
 incubate at 37  °C for 10-18 h 
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 control colony density and size (stable at 4  °C until further notice) 
 pick single colony from the agar using a pipette with sterile tip 
 put the colony in the preculture (5 mL LB Broth supplemented with 100 µg/mL 
ampicillin)  
 vortex during 10 sec 
 put the preculture on the agitator at 37  °C for 10-18 h 
 put 250 µL of preculture in main culture (250 mL LB Broth supplemented with 100 
µg/mL ampicillin)  
 put the main culture on the agitator at 37 °C for 10-18 h 
 harvest bacteria from the LB Broth culture by centrifugation (15 min, 6000 rcf, 4 °C) 
 plasmid DNA isolation is performed according to the manufacturer’s instructions 
(Nucleobond Ax, Machinery-Nagel) 
 quantify plasmid DNA by measuring the optical density (OD) at 260 nm (OD260 = 1 
corresponds to 50 µg/mL). Purity is evaluated by measuring the ratio OD260/280. 
Values should lie between 1.8 and 2.1.  
 
4.13.3 Transient transfection assays 
The concept of electroporation is based on the relatively weak structure of the 
phospholipid bilayer’s and its ability to reassemble after disintegrating. After breaking 
areas of the membrane by applying a quick voltage shock, a transient, permeabilized 
state can be used to charge cells with different molecules, either through simple 
diffusion in the case of small molecules, or through an electrophoretically driven 
process allowing passage through the damaged membrane – as is the case for DNA 
transfer. Transfections of K562 cells are performed by electroporation using a Bio-Rad 
gene Pulser. TF-1 and HEL cells were transfected using a nucleofector from Amaxa 
following manufacturer’s instructions using KIT V. Cells in the exponential growth 
phase are resuspended in RPMI 1640 Medium. 
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For electroporation: 
3.75*106 cells at a concentration of 1.5*107 cells/ mL are electroporated at 250 V and 
500 µF.  
For nucleofection:  
5*106 cells at a concentration of 5*107 cells/ mL nucleofector solution, are 
electroporated using program T03 for TF-1 cells and X05 for HEL cells. 
 Five micrograms of luciferase reporter gene construct and 5µg phRL-SV40-plasmid 
expressing Renilla are used for each pulse. For co-transfection assays, 5 µg of 
expression plasmid are added to this mixture.  
 After 24 h, cells are harvested and resuspended in growth medium (RPMI/FCS 10%) 
at a final concentration of 106 cells/mL with or without treatments (48h). 
  Dual-GloTM Luciferase Reagent (75µL) and Dual-GloTMStop&GlowReagent 
(Promega) are added according to the manufacturers recommendations. Firefly and 
Renilla luciferase activities are measured using a Orion microplate luminometer 
(Berthold) by integrating light emission for 10 s. Results are expressed as a ratio of 
arbitrary units of firefly luciferase activities normalized to Renilla luciferase activities. 
 
4.14 Statistics  
Data were expressed at the mean +/- standard deviation (SD). Statistical significance 
was assessed by Students t-test P-values below 0.05 were considered as statistically 
significant (*P ≤ .05, **P ≤ .01, ***P ≤ .001).  
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5 Results 
In the nineteenth century, TNFα was identified as a negative regulator of erythropoiesis 
116,121,122. In the meantime, a critical role for TNFα has been established in many forms of 
cancer 130 and inflammation related anemia 134. In order to elucidate and generalize the 
inhibiting effect of TNFα on erythroid differentiation, we used the hematopoietic cell 
lines K562, HEL, and TF-1 as well as purified CD34+ cells as cellular models to mimic 
anemia in the presence of TNFα. Due to their differentiating potential, erythroleukemia 
cell lines present a good experimental system to study erythroid differentiation. Various 
agents can induce K562 and HEL towards the erythroid differentiation pathway 191-194. In 
this study we used Acla, Dox, He, and Epo to induce erythroid differentiation. TF-1, a 
factor dependent, Epo-sensitive erythroleukemia cell line, was shown to produce 
hemoglobin after Epo treatment 151,152,195. Moreover, the primary umbilical CD34+ cells 
are known to differentiate towards the erythroid differentiation pathway using Epo.  
The aim of this study is to decode the effect of the proinflammatory cytokine TNFα on 
the hemoglobinization level, the RNA and protein levels of erythroid specific genes as 
well as the regulation by the major erythroid transcription factor GATA-1 and involved 
cell signaling pathways.  
5.1 Effect of TNFα on hemoglobin synthesis 
5.1.1 Effect of TNFα  on hemoglobin synthesis, proliferation and mortality 
in cell lines  
In order to measure the effect of TNFα on induced erythroid differentiation, we 
investigated the effect of the cytokine on hemoglobin synthesis, cell growth, and cell 
death. At least 100 cells were counted. The cells were retained as “benzidine positive” 
(benzidine +), if they were colored in green-blue as shown on figures 7, 8, or 9.  
Effect of TNFα  in K562 cells 
 Hemoglobin synthesis 
When TNFα was added to the cell culture medium 1 hour prior to Acla, Dox, or He 
treatment, a reduction of the number of benzidine + cells was observed, whereas a TNFα 
or Remicade pretreatment alone, used as a control, did not influence hemoglobin 
synthesis in K562 cells (Fig. 7A).   
    
  
Results 
45 
The K562 cells turned out to be inducible towards the erythroid pathway with all 
substances: Acla, Dox and He. Results show a reduction of hemoglobinization whenever 
cells were treated with TNFα and this independently of the chemical inducer used (Fig. 
7B).  
Acla (10 nM) induced a hemoglobinization rate of 48%, which was significantly reduced 
to 23% after addition of TNFα (Fig 7B). Moreover, the TNFα inhibitor Remicade (R) 
(100 µg/mL) significantly reduced the inhibitory effect of TNFα, resulting in a final 
hemoglobinization rate of 47% (Figure 7B). 
Following addition of 40 nM Dox, 31% of cells were benzidine +, and after addition of 
TNFα, a significant decrease could be observed. Compared to other chemical inducers, 
Dox had also an effect on cell size. Furthermore, Remicade abolished the effect of the 
cytokine whenever added in combination with Dox (25%) (Fig. 7B).  
After 3 days of treatment with He (30 µM), 78% of cells were benzidine +, which was 
significantly decreased to 57% by retreating the cells with 20 ng/mL TNFα. This 
inhibitory effect of TNFα was reversed by the addition of Remicade to 77% (Fig. 7B).  
 cell growth 
Treatment of K562 cells with He reduced the cell growth by 23%, and the addition of 
TNFα alone or in combination with He decreased cell growth of 22% and 31%. Using 
Acla alone reduces the proliferation by 18%. In combination with TNFα, the proliferation 
is restricted by 44%. Treating the cells during 3 days with Dox induces a reduction of 
52%, taking TNFα as supplement stopped proliferation of 68% (Fig. 7B).  
 viability 
To analyze the toxicity of the different treatments, the Trypan viability assay was 
realized. K562 Trypan mean values did not exceed 7% of mortality rate after the different 
treatments (Fig. 7B).  
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Figure 7: Effect of TNFα on hemoglobin synthesis in K562 cells. Cells were pretreated with or 
without Remicade (R) (100 µg/mL) and/or TNFα (T) (20 ng/mL) prior to three days of 
differentiation with 10 nM Acla, 40 nM Dox, or 30 µM He. A) Hemoglobinized cells were stained 
on day 3 using the benzidine method. B) Percentages of benzidine + cells, cell growth and 
Trypan + cells. Untreated cells were used as control (c). Values are reported as the means (+/- 
standard deviation, SD) of 7 independent experiments. All benzidine results were significant. 
(***P ≤ .05) 
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Effect of TNFα  in HEL cells 
 Hemoglobin synthesis 
HEL cells were induced towards the erythroid pathway using He (Fig. 6A). Results 
showed that 20 ng/mL of TNFα treatment 1 hour prior to 3 days of treatment with 30 µM 
He reduced the hemoglobinization rate to 39% when compared to He treatment alone 
(61%) (Fig. 8B). Remicade alone had no influence on hemoglobinization rate, but 
rescued the inhibitory effect of TNFα when treated in combination with He (60%) (Fig. 
8B). 
 cell growth 
In HEL cells, the different treatments had no significant effect on cell growth (Fig. 8B).  
 viability 
To analyze the toxicity of the different treatments, the Trypan viability assay was 
realized. Trypan mean values did not exceed 7% of mortality rate after the different 
treatments (Fig. 8B). 
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Figure 8: Effect of TNFα on hemoglobin synthesis in HEL cells. Cells were pretreated with or 
without Remicade (R) (100 µg/mL) and/or TNFα (T) (20 ng/mL) prior to three days of 
differentiation with 30 µM He. A) Hemoglobinized cells were stained on day 3 using the 
benzidine method. B) Percentages of benzidine + cells, cell growth and Trypan + cells. 
Untreated cells were used as control (c). Values are reported as the means (+/- standard 
deviation, SD) of 7 independent experiments. (***P ≤ .001) 
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Effect of TNFα  in TF-1 cells 
 Hemoglobin synthesis 
Benzidine staining of control TF-1 cells revealed no benzidine positive cells (Fig. 9). 
After treating the cells with 10 U/mL Epo, benzidine staining revealed hemoglobinized 
green-blue colored cells, and TNFα had a visible inhibitory effect on this differentiation. 
The addition of Remicade in combination with TNFα rescued the inhibitory effect of the 
cytokine (Fig. 9A). 
Quantifications of benzidine positive cells showed up to 44% of hemoglobin producing 
cells in the presence of Epo alone and only 24% after the pre-treatment with TNFα 
providing evidence that erythroid differentiation was significantly inhibited during TNFα 
treatment. Moreover, the TNFα inhibitor Remicade (R) (100 µg/mL) significantly 
reduced the inhibitory effect of TNFα, resulting in a final hemoglobinization rate of 35% 
(Figure 9B).  
 cell growth 
TNFα did not show any effect on the viability of Epo-induced TF-1 cells (Fig. 9B).  
 viability 
To analyze the toxicity of the different treatments, the Trypan viability assay was realized 
after each treatment. Trypan mean values did not exceed 3% of mortality rate after the 
different treatments (Fig. 9B). 
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Figure 9: Effect of TNFα  on hemoglobin synthesis in TF-1 cells. Cells were pretreated with or 
without Remicade (R) (100 µg/mL) and/or TNFα (T) (20 ng/mL) prior to three days of 
differentiation with 10 U/mL Epo. A) Hemoglobinized cells were stained on day 3 using the 
benzidine method. B) Percentages of benzidine + cells, cell growth and Trypan + cells. 
Untreated cells were used as control (c). Values are reported as the means (+/- standard 
deviation, SD) of 5 independent experiments. (**P ≤ .01, ***P ≤ .001) 
 
K562, HEL, and TF-1 cells were able to differentiate towards the erythroid 
pathway using He, Acla, Dox, or Epo depending on the cell line used. TNFα 
decreased the hemoglobinization rate independently of the inducer used. TNFα had 
an inhibitory effect on both chemical as well as Epo-induced erythroid 
differentiation. The different erythroid inducers did not affect cell viability and cell 
growth varied depending on the substances used. 
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5.1.2 Effect of TNFα  on hemoglobin synthesis in CD34+ hematopoietic 
progenitor cells 
5.1.2.1 CD34+ purity  
In order to generalize the previous findings of the inhibitory effect of TNFα on the three 
cell lines, we wanted to consolidate these results by using healthy human early 
progenitors, which can be differentiated along the erythroid differentiation pathway by 
Epo. 
In order to handle CD34+ cells gained from cord blood, we performed magnetic cell 
labeling and cell sorting. In order to assess CD34+ purity we performed flow cytometry 
analysis. The purity of the eluted CD34+ cells showed that an average purity of 92% 
varying between 89% and 96% (Fig. 10).  
 
 
Figure 10: Purity assessment of CD34+ cell fraction after CD34+ magnetic cell sorting. A) 
Histogram of CD34+ cells after magnetic cell sorting by flow cytometry. The CD34+ cell 
fraction M2 is 89% pure. One representative result of 4 independent experiments. B) Initial 
volume, final CD34+ cell number and cell purity of four umbilical cord blood samples. 
 
5.1.2.2 CD34+ differentiation  
In order to differentiate CD34+ cells gained from cord blood, we supplemented our cells 
with a cocktail of cytokines as mentioned in Material and Methods. 12 different cord 
blood cultures were processed and benzidine staining was realized at different time points 
(Fig. 11). Quantifications of these benzidine results showed an increase in 
hemoglobinized cells in a time dependent matter. 
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Figure 11: Benzidine staining of CD34+ cells treated with a cocktail of cytokines. (days 0–3, 
10 ng/mL IL-3 and 10 ng/mL SCF; days 3–7, 10 ng/mL IL-3, 10 ng/mL SCF, and 2 U/mL EPO; 
days 7–9, 10 ng/mL SCF and 2 U/mL EPO; and after day 9, 2 U/mL EPO days 0 to 3, 10 with 2 
U/mL Epo). A) Hemoglobinized cells were stained on indicated days using the benzidine method. 
B) Percentages of benzidine + cells of distinct cord blood cultures on indicated days.  
5.1.2.3 Effect of TNFα on Epo-differentiated CD34+ cells  
Treating CD34+ cells for 7 or 10 days with Epo alone or in combination with TNFα 
showed differences in the number of benzidine + cells over the time (Fig. 12). Thus 
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TNFα had a similar inhibitory effect on human hematopoietic CD34+ progenitor cells 
than in the three cell lines. This inhibitory effect was even enhanced over time (Fig. 12). 
 
 
Figure 12: Benzidine staining of CD34+ cells treated or not with 20 ng/mL TNFα and a 
cocktail of cytokines (days 0–3, 10 ng/mL IL-3 and 10 ng/mL SCF; days 3–7, 10 ng/mL IL-3, 10 
ng/mL SCF, and 2 U/mL EPO; days 7–9, 10 ng/mL SCF and 2 U/mL EPO) A) Hemoglobinized 
cells were stained on day 7 and day 10 using the benzidine method. B) Percentages of benzidine 
+ cells of distinct cord blood cultures on day 7 and day 10. (One representive result of 3 
independent experiments) 
 
A CD34+ cell purity of 89-96% was gained from umbilical cord blood. The 
effect of the cytokine TNFα revealed a first insight of the inhibitory effect of this 
cytokine on these differentiating CD34+ human progenitor cells.  
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5.2 Effect of TNFα on NF-κB induction  
In order to ascertain that TNFα is functional in our experimental conditions, EMSA 
assays were performed using 10 µg of nuclear extracts and a labeled NF-κB consensus 
probe. Indeed, TNFα is a well-known inducer of the canonical NF-κB pathway leading to 
the activation and translocation of NF-κB (p50/p65) dimer into the nucleus. Moreover, 
induction of NF-κB binding activity has been shown to be involved in the repression of 
globin gene expression 196.  
Effect of TNFα  on NF-κB induction in K562 cells 
Results show an increased NF-κB (p50/p65) binding activity after treating K562 cells 
with TNFα. Using the erythroid differentiation inducers alone, no stimulation of the NF-
κB pathway was observed (Fig. 13), whereas pretreating the K562 cells with TNFα 
induces the binding of the p50/p65 dimer as shown by immunodepletion assays. The use 
of Remicade abrogated the TNFα-induced NF-κB binding activity independently of the 
inducer used (Fig. 13).  
Effect of TNFα  on NF-κB induction in HEL cells 
Analysis of the NF-κB binding capacity in HEL cells shows an increase of the binding 
capacity after treating the cells with TNFα alone, or in combination with He, which is 
decreased after simultaneous addition of Remicade (Fig. 13). 
Effect of TNFα  on NF-κB induction in TF-1 cells 
Analysis of the NF-κB binding capacity in TF-1 cells showed an increase of the binding 
capacity after treating the cells with TNFα in combination with Epo, which is decreased 
after simultaneous addition of Remicade (Fig. 13).  
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Figure 13: Effect of TNFα and Remicade on NF-κB DNA binding activity analyzed by EMSA. 
EMSA assay was performed on 10 µg nuclear extracts using NF-κB consensus (NF-κBc)-32P-
labeled probe and the use of p50 and p65 antibodies (ab) revealed a p50/p65-DNA complex after 
K562 cells treated with TNFα and Hemin. Nuclear extracts were prepared from K562 (A), HEL 
(B), and TF-1 (C) cells treated with 10 nM Acla, 40 nM Dox, 30 µM He, or 10 U/mL Epo for 3 
days in the presence or absence of 20 ng/mL TNFα (T) and/or 100 µg/mL of Remicade (R). 
Untreated cells were used as controls (c). (One representative result of 3 independent 
experiments) 
In our experiments, TNFα  activation of NF-κB was efficient and concomitant to 
inhibition of differentiation in the three cell lines, independently of the inducer 
used. The use of Remicade reversed this effect.  
 
5.3 Effect of TNFα on major erythroid transcription factors 
5.3.1 Effect of TNFα  on mRNA expression 
We then investigated the effect of TNFα on erythroid transcription factors. First we 
investigated the effect of the cytokine on the major hematopoietic transcription factor 
GATA-1. Moreover, other important erythroid transcription factors such as NF-E2 or 
EKLF were also investigated in this study as they were shown to act downstream or 
together with GATA-1 7,26,197, and to be also required for specific gene expression such 
as globin or HMBS 42,43,198-200. Indeed, GATA-1 is known to be regulated by a number of 
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coregulators acting as coactivator (FOG-1) or as corepressor (PU.1) 201. Thus FOG-1 was 
shown to act as a cofactor of GATA-1 in erythroid differentiation 35, since mice lacking 
FOG-1 die during mid-embryonic development with severe anemia 202. Moreover, it is 
known that GATA-1 and GATA-2 expression are inversely expressed during 
erythropoiesis.  Indeed, for terminal differentiation, GATA-2 has to be suppressed 203. 
In order to evaluate whether TNFα affects mRNA level of transcription factors known to 
play a role in erythropoiesis, we analyzed GATA-1 as well as other key erythroid 
transcription factor mRNA expression after TNFα treatment. mRNA levels were 
analyzed by semi-quantitative RT-PCR, or qRT-PCR.  
Effect of TNFα  on mRNA expression in K562 cells 
After quantifications of qRT-PCR analysis of 5 independent experiments, we observed a 
significant 1.7 fold increase of constitutive GATA-2 mRNA after TNFα treatment and a 
simultaneous decrease in GATA-1 and EKLF mRNA expression (Fig.14A). Similarly, in 
Acla-induced K562 cells, a significant increase in GATA-2 and a parallel significant 
decrease in GATA-1, FOG-1, NF-E2 and EKLF mRNAs’ expression was observed after 
TNFα treatment in Acla-treated cells (Fig. 14B). 
Effect of TNFα  on mRNA expression in HEL cells 
In HEL cells, RT-PCR analysis showed a decrease of the constitutive amount of GATA-1 
mRNA in the cells (0.69 fold) after TNFα treatment. GATA-1 mRNA expression was 
reduced after TNFα addition in He-treated cells (Fig. 14C).  
Effect of TNFα  on mRNA expression in TF-1 cells 
In TF-1 cells, TNFα addition resulted in a decrease of GATA-1 and NF-E2 and a parallel 
increase in GATA-2 mRNA expression when compared to Epo-treated cells alone (Fig. 
14D).  
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Figure 14: Effect of TNFα on erythroid transcription factor mRNA expression. A) qRT-PCR 
analysis expressed in fold change of erythroid transcription factor mRNA expression after TNFα 
treatment of uninduced K562 cells compared to control cells. B) qRT-PCR analysis expressed in 
fold change of erythroid transcription factor mRNA expression after TNFα treatment of Acla-
induced K562 cells compared to Acla treatment alone. C) RT-PCR of total RNA was prepared 
from treated (30 µM He) or untreated HEL cells in the presence or absence of 20 ng/mL TNFα 
(T). (One representative result of 3 independent experiments) D) qRT-PCR analysis expressed in 
fold change of erythroid transcription factor mRNA expression after TNFα treatment of Epo-
induced TF-1 cells compared to Epo treatment alone. The relative amounts of mRNA were 
normalized to the housekeeping gene MRPS14 and for qRT-PCR results; data are means +/- SD 
of 5 independent experiments. (*P ≤ .05, **P ≤ .01, ***P ≤ .001)  
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5.3.2 Effect of TNFα  on protein analysis 
5.3.2.1 Effect of TNFα on GATA-1 protein expression 
We then performed GATA-1 western blot analysis on nuclear extracts from TNFα-
treated constitutive or induced cells.  
Effect of TNFα  on GATA-1 protein expression in K562 cells 
We investigated the effect of TNFα on the constitutive and induced GATA-1 protein 
expression after 3-day treatment. Compared to control, a 2.4 fold induction was observed 
after 3 days of Acla treatment, which is in turn decreased after addition of TNFα (1.2 fold 
induction) (Fig. 15A). Treating K562 cells with Dox and TNFα sowed a reduction when 
compared to Dox treatment alone. The results of He treatments showed a decrease of 
GATA-1 protein expression, when treated in combination with TNFα. Cotreatment with 
Remicade abrogated the reductive effect of TNFα on Acla- or Dox-induced GATA-1 
protein expression (Fig. 15A), suggesting that the inhibiting effect of TNFα on 
hemoglobinization occurs via GATA-1 transcription factor activity. Remicade abrogated 
the inhibitory effect of TNFα on GATA-1 protein expression. 
Effect of TNFα  on GATA-1 protein expression in HEL cells 
In HEL cells, TNFα treatment resulted in a decrease of GATA-1 protein compared to the 
control after TNFα treatment. In He-induced cells, we could observe an inhibitory effect 
of TNFα on GATA-1 protein expression. Remicade abrogated this effect in both non-
treated and induced cells (Fig. 15B).  
Effect of TNFα  on GATA-1 protein expression in TF-1 cells 
In TF-1 cells, analysis of GATA-1 protein expression using the C-20 ab revealed an 
increase of GATA-1 protein expression, when compared to control cells (GM-CSF). 
TNFα addition resulted in a reduction of the protein level, and the use of Remicade 
reversed this effect of the cytokine (Fig. 15C).  
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Figure 15: Western blot analysis of GATA-1 protein expression. 20 µg nuclear protein extracts 
were used. β-actin was used as internal control. A) K562 cells were pretreated with or without 
Remicade (R) (100 µg/mL) and/or TNFα (T) (20 ng/mL) prior to three days of differentiation 
with 10 nM Acla, 40 nM Dox, or 30 µM He. B) HEL cells were pretreated with or without 
Remicade (R) (100 µg/mL) and/or TNFα (T) (20ng/mL) prior to three days of differentiation with 
30 µM He. C) TF-1 cells were pretreated with or without Remicade (R) (100 µg/mL) and/or 
TNFα (T) (20 ng/mL) prior to three days of differentiation with 10 U/mL Epo. (One 
representative result of 3 independent experiments) 
TNFα had an inhibitory effect on GATA-1 mRNA as well as on induced GATA-
1 protein expression in all three cell lines, both after chemical induction by Acla, 
Dox, or He and after Epo-induction. The anti-TNFα ab neutralized the 
inhibitory effect of TNFα.  
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5.3.2.2 Effect of TNFα on FOG-1 protein expression 
FOG-1 encodes a protein of 995 amino acids containing multiple Zn fingers 28. FOG-1-/- 
mice are dying early in embryonic development from severe anemia 202. These mice 
show a block in erythroid development at a stage similar to that observed in GATA-1 
deficient mice. This fact provides evidence that FOG-1 and GATA-1 function as 
cooperators in a coordinate way in erythroid differentiation 204. In order to investigate the 
role of TNFα on the level of FOG-1 we analyzed this protein expression by western blot.  
Effect of TNFα  on FOG-1 protein expression in K562 cells 
First western blot results showed an inhibitory effect of TNFα on both constitutive as 
well as induced FOG-1 protein expression. Results showed an increase after treating the 
cells for 3 days with Acla. This effect is reduced to after TNFα addition (Fig. 16A).  
Effect of TNFα  on FOG-1 protein expression in HEL cells 
Results showed an increase of FOG-1 protein expression in He-induced HEL cells,  
which was reduced after TNFα addition (Fig. 16B).  
Effect of TNFα  on FOG-1 protein expression in TF-1 cells 
In Epo-induced TF-1 cells we could observe an increase in FOG-1 protein expression 
compared to control. This induction was reduced after TNFα treatment and the use of 
Remicade reversed this inhibitory effect (Fig. 16C).  
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Figure 16: Western blot analysis of FOG-1 protein expression. 20 µg nuclear protein extracts 
were used. β-actin was used as internal control. A) K562 cells were pretreated with or without 
Remicade (R) (100µg/mL) and/or TNFα (T) (20 ng/mL) prior to three days of differentiation with 
10 nM Acla. B) HEL cells were pretreated with or without TNFα (T) (20 ng/mL) prior to three 
days of differentiation with 30 µM He. C) TF-1 cells were pretreated with or without Remicade 
(R) (100 µg/mL) and/or TNFα (T) (20 ng/mL) prior 3 days of differentiation with 10 U/mL Epo. 
(One representative result of 3 independent experiments) 
 
TNFα showed an inhibitory effect on FOG-1 protein expression in K562, HEL, and 
TF-1 cells independently of the inducer used. 
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5.3.2.3 Effect of TNFα on NF-E2 protein expression  
After observing the inhibitory effect of TNFα on NF-E2 mRNA expression, we then 
analyzed the effect of TNFα on the protein expression of the erythroid transcription 
factor NF-E2.  
Effect of TNFα  on NF-E2 protein expression in K562 cells 
By investigating the role of TNFα on NF-E2 protein expression, we saw an inhibitory 
effect of TNFα on constitutive NF-E2 protein expression in K562 cells (Fig. 17A).  
Effect of TNFα  on NF-E2 protein expression in HEL cells  
Treating HEL cells for 3 days with TNFα resulted in a strong downregulation of the 
protein in untreated and He-induced cells (Fig. 17B).  
Effect of TNFα  on NF-E2 protein expression in TF-1 cells 
In TF-1 cells NF-E2 protein expression analysis showed a downregulation of NF-E2 
protein expression after TNFα treatment in Epo-stimulated TF-1 cells. Remicade 
reversed this inhibitory effect (Fig. 17C). 
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Figure 17: Western blot analysis of NF-E2 protein expression. 20 µg nuclear protein extracts 
were used. β-actin was used as internal control. A) K562 cells were pretreated with or without 
20 ng/mL TNFα (T) prior to three days of differentiation with 10 nM Acla. B) HEL cells were 
pretreated with or without 20 ng/mL TNFα (T) prior to three days of differentiation with 30 µM 
He. C) TF-1 cells were pretreated with or without Remicade (R) (100 µg/mL) and/or TNFα (T) 
(20 ng/mL) prior 3 days of differentiation with 10 U/mL Epo. (One representative result of 3 
independent experiments)  
 
In all three cellular models, TNFα had an inhibitory effect on the erythroid 
transcription factor NF-E2.  
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5.3.2.4 Effect of TNFα on GATA-2 protein expression 
We investigated the effect of TNFα on GATA-2 protein expression. Indeed GATA-2 is 
mainly expressed during early hematopoiesis, whereas GATA-1 has been shown to be 
responsible for terminal differentiation 203. 
Effect of TNFα  on GATA-2 protein expression in K562 cells 
In order to investigate the effect of TNFα on GATA-2 protein expression, K562 cells 
were treated for three days with the different inducers in the presence or absence of 
TNFα. Results show an upregulation of GATA-2 protein expression after TNFα 
treatment independent of the inducer used (Fig. 18A). Moreover, TNFα showed an 
inducing effect on constitutive GATA-2 protein expression 
Effect of TNFα  on GATA-2 protein expression in HEL cells 
In HEL cells were treated for 3 days with He in the presence or absence of TNFα. Results 
show an increase of GATA-2 protein expression compared to the control (Fig. 18B).  
Effect of TNFα  on GATA-2 protein expression in TF-1 cells 
In TF-1 cells GATA-2 protein expression analysis showed the same expression pattern. 
A 1.7 fold increase in GATA-2 protein expression was already observed after 8 hours of 
TNFα treatment and was maintained for up to 72 hours in Epo-treated TF-1 cells. This 
inductive effect for GATA-2 was partially abrogated by the use of Remicade (R) after 3 
days of treatment (Fig. 18C).  
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Figure 18: Western blot analysis of GATA-2 protein expression. 20 µg nuclear protein extracts 
were used. β-actin was used as internal control. A) K562 cells were pretreated with or without 
20 ng/mL TNFα (T) prior to three days of differentiation with 10 nM Acla, 40 nM Dox, or 30 µM 
He. B) HEL cells were pretreated with or without 20 ng/mL TNFα (T) prior to three days of 
differentiation with 30 µM He. C) TF-1 cells were pretreated with or without Remicade (R) (100 
µg/mL) and/or TNFα (T) (20 ng/mL) prior to 8, 12, 24, 48, or 72 hours of differentiation with 10 
U/mL Epo. (One representative result of 3 independent experiments) 
 
Independently of the nature of the cell line or the inducer used, TNFα reversed 
the physiological balance between GATA-1 and GATA-2 normally present 
during erythropoiesis. 
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5.3.2.5 Effect of TNFα on PU.1 protein expression 
After analyzing the effect of TNFα on the transcription factor GATA-1, we investigated 
the effect of this cytokine on the transcription factor PU.1, which is described in the 
literature as a potent inhibitor of GATA-1. An antagonism between GATA-1 and PU.1 
has already been described, which is important for determining lineage commitment 
during hematopoiesis (erythroid versus myeloid) 205. qRT-PCR analysis did not show any 
significant variations after TNFα treatment. In order to investigate the role of TNFα on 
the level of PU.1 we analyzed PU.1 protein expression by western blot.  
Effect of TNFα  on PU.1 protein expression in K562 cells 
TNFα as well as Remicade treatment resulted in a reduction of constitutive PU.1 protein 
expression in K562 cells. Compared to control, a reduction was observed after 3 days of 
Acla treatment, which is not changed after addition of TNFα (Fig. 16A). Results of He 
treatments showed a decrease of PU.1 protein expression, whenever treated in 
combination with TNFα  (0.7 fold) or not (0.8 fold) (Fig. 19A).  
Effect of TNFα  on PU.1 protein expression in HEL cells 
HEL cells were treated for 3 days with He in the presence or absence of TNFα and/or 
Remicade. Results show a similar increase of PU.1 protein expression compared to the 
control whatever treatment was realized (Fig. 19B).  
Effect of TNFα  on PU.1 protein expression in TF-1 cells 
In TF-1 cells PU.1 protein expression analysis did not reveal any important variations 
compared to the controls (Fig. 19C).  
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Figure 19: Western blot analysis of PU.1 protein expression. 20 µg nuclear protein extracts 
were used. β-actin was used as internal control. A) K562 cells were pretreated with or without 
Remicade (R) (100µg/mL) and/or TNFα (T) (20 ng/mL) prior to three days of differentiation with 
10 nM Acla or 30 µM He. B) HEL cells were pretreated with or without Remicade (R) 
(100µg/mL) and/or TNFα (T) (20 ng/mL) prior to three days of differentiation with 30 µM He. C) 
TF-1 cells were pretreated with or without Remicade (R) (100 µg/mL) and/or TNFα (T) (20 
ng/mL) prior 3 days of differentiation with 10 U/mL Epo. (One representative result of 3 
independent experiments) 
 
No general conclusions can be made for PU.1, since the effect of TNFα  on 
PU.1 protein expression varied with the inducer and the cell line used.  
 
 
 
 
 
 
    
  
Results 
68 
5.3.3 Effect of TNFα  on GATA-1/FOG-1 interaction 
To assess whether TNFα treatment could further affect the interaction between GATA-1 
and FOG-1, besides both proteins downregulation, GATA-1 was immunoprecipitated 
using the C-20 GATA-1 ab. GATA-1 was revealed by western blot using the N1 GATA-
1 ab.  
As previously shown a decrease in GATA-1 protein expression was observed in cells 
treated with TNFα independently of the inducer used. Co-immunoprecipitated FOG-1 
was present in induced HEL cells confirming its interaction with GATA-1 during 
erythroid cell fate decision (Fig. 20A). After TNFα treatment, immunoblots showed a 
complete abrogation of the constitutive GATA-1/FOG-1 complex in untreated HEL cells 
(Fig. 20A). Moreover, in He-induced HEL cells, we could observe a slight decrease of 
FOG-1 and GATA-1 proteins in the complex (Fig. 20A). Similarly TNFα decreased the 
amount of both interaction partners in Epo-induced TF-1 cells (Fig. 20B). The 
persistence of FOG-1 in the immunoprecipitation showed that GATA-1/FOG-1 
interaction was not abrogated by TNFα in differentiated cells. The reduction of co-
immunoprecipitated proteins was then rather due to a decrease in the amount of the 
GATA-1/FOG-1 complex in correlation with the cofactors downregulation than to a 
prevented physical interaction. However, this decrease in GATA-1/FOG-1 complex 
might lead to a less efficient transactivation of erythroid genes (Fig. 20A, B). 
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Figure 20: Immunoprecipitation analysis of GATA-1/FOG-1 protein interaction. 500µg 
total protein extracts were immunoprecipitated using the GATA-1 antibody C-20. 20 µg nuclear 
protein extracts were used for input. A) HEL cells were pretreated with or without TNFα (T) (20 
ng/mL) prior to three days of differentiation with 30 µM He. B) TF-1 cells were pretreated with 
or without TNFα (T) (20 ng/mL) prior 3 days of differentiation with 10 U/mL Epo.  
 
TNFα  abrogates constitutive GATA-1/FOG-1 complex formation in untreated 
HEL cells, whereas its inhibiting effect in differentiated cells is correlated with 
the downregulation of GATA-1 and FOG-1 protein expression in HEL and TF-1 
cells.  
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5.3.4 Effect of TNFα  on posttranslational modifications of GATA-1 
5.3.4.1 Effect of TNFα on GATA-1 and FOG-1 degradation 
As we saw that TNFα had an inhibitory effect on the amount of GATA-1 and FOG-1, we 
investigated the possibility that the decrease in GATA-1 and FOG-1 expression resulted 
in protein degradation. 
Effect of TNFα  on GATA-1 degradation in K562 cells  
Results showed that by using lactacystin, a proteasome inhibitor, we were able to 
abrogate the inhibitory effect of TNFα on both constitutive as well as induced GATA-1 
protein expression in K562 and HEL cells (Fig. 21A).  
Effect of TNFα  on GATA-1 and FOG-1 degradation in HEL cells  
Results showed that by using lactacystin, a proteasome inhibitor, we were able to 
abrogate the inhibitory effect of TNFα on both constitutive as well as induced GATA-1, 
and induced FOG-1 protein expression in HEL cells (Fig. 21B).  
Effect of TNFα  on GATA-1 and FOG-1 degradation in TF-1 cells  
Results showed that lactacystin prevented the inhibiting effect of TNFα on FOG-1 but 
not on GATA-1. This allowed us to conclude that the reduction of FOG-1 expression in 
TF-1 resulted at least in part in its degradation by the proteasome in TNFα treated TF-1 
cells (Fig. 21C).  
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Figure 21: Western blot analysis of GATA-1 and FOG-1 protein degradation. 20 µg nuclear 
protein extracts were used. β-actin was used as internal control. A) K562 and B) HEL cells were 
pretreated with or without lactacystin (Lact) (1µM), and/or TNFα (T) (20 ng/mL) prior to one 
day of incubation with 10nM Acla, or 30µM He. C) TF-1 cells were pretreated with or without 
1µM lactacystin (Lact), Remicade (R) (100µg/mL) and/or TNFα (T) (20 ng/mL) prior to one day 
of differentiation with 10 U/mL Epo. (One representative result of 3 independent experiments)  
 
Analyzing the effect of an inhibitor of proteasomal degradation, lactacystin, 
on the inhibition of erythroid differentiation by TNFα, pointed to a 
proteasomal dependent degradation of GATA-1 and/or FOG-1 protein 
expression in the different cell lines.  
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5.3.4.2 Effect of TNFα on GATA-1 acetylation 
Besides the above-discussed degradation of GATA-1, this transcription factor might 
underlie other posttranscriptional modifications such as phosphorylation, acetylation, and 
sumoylation. As acetylation was shown to clearly affect GATA-1 transcriptional 
activation, we then assessed its role after TNFα treatment. As acetylation of GATA-1 is 
described to be essential for binding to DNA in vivo, and thus activation of target genes, 
we analyzed the acetylation status of GATA-1 after TNFα treatment. After 
immunoprecipitating GATA-1, the use of an anti-acetylated antibody revealed a 
complete absence of acetylation after TNFα treatment in He-induced K562 cells, which 
would suggest a possible loss of GATA-1’s ability to bind DNA after TNFα treatment 
(Fig. 22).  
 
 
Figure 22: Immunoprecipitation analysis of acetylated GATA-1 protein. 500µg total protein 
extracts were immunoprecipitated using the GATA-1 antibody C-20. 20 µg nuclear protein 
extracts were used for input. K562 cells were with or without TNFα (T) (20 ng/mL) prior to three 
days of differentiation with 30 µM He.  
 
TNFα  showed an inhibitory effect on the acetylation status of GATA-1 protein 
expression in He-induced K562 cells. This result gives first hints about an effect 
of TNFα on GATA-1 binding capacity in vivo.  
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5.4 Effect of TNFα on GATA-1 transcriptional regulation 
mechanisms 
5.4.1 Effect of TNFα on GATA-1 binding capacity 
5.4.1.1 Effect of TNFα on GATA-1 binding capacity analyzed by EMSA assay 
Since TNFα treatment was shown to inhibit erythroid transcription factor expression, we 
investigated its effect on the hematopoietic transcription factor GATA-1 binding activity. 
Ten micrograms of nuclear extracts were analyzed by EMSA using a GATA consensus 
probe as described in Materials and Methods.  
Effect of TNFα  on GATA-1 binding capacity in K562 cells by EMSA assay 
Independent of the inducer of erythroid differentiation, EMSA experiments showed a 
decrease in GATA-1 binding activity after 3 days of TNFα treatment (Fig. 23A). 
Moreover, TNFα had an effect on constitutive binding in K562 cells. Acla induced an 
increase in GATA-1 binding activity, which in turn was diminished by TNFα. The 
GATA-1 forming complex in EMSA was identified by immunodepletion experiments 
using a GATA-1 ab. Remicade abrogated the inhibitory effect of the cytokine on induced 
GATA-1 binding capacity.  
Effect of TNFα  on GATA-1 binding capacity in HEL cells by EMSA assay 
In HEL cells, the constitutive binding capacity of GATA-1 is decreased after TNFα 
addition. Using He as an erythroid inducer, we saw an increase of GATA-1 binding to its 
DNA sequence. This effect was slightly reduced after supplementing with TNFα (Fig. 
20B). The use of Remicade abrogated the inhibitory effect of TNFα on constitutive 
GATA-1 binding activity (Fig. 23B).  
Effect of TNFα  on GATA-1 binding capacity in TF-1 cells by EMSA assay 
Results obtained with TF-1 cells showed an important constitutive GATA-1 binding 
activity in Epo-treated cells. TNFα had an inhibitory effect on Epo-induced GATA-1 
binding activity, which is abrogated after Remicade addition (Fig. 23C). The GATA-1 
forming complex in EMSA was confirmed by immunodepletion experiments using a 
GATA-1 ab. 
    
  
Results 
74 
 
Figure 23: Effect of TNFα and Remicade on GATA-1 DNA binding activity analyzed by 
EMSA. EMSA assay was performed on 10 µg nuclear extracts using GATA-1 consensus (GATA-
1)-32P-labeled probe and the use of GATA-1 and GATA-2 antibodies (G-1ab, G-2ab) revealed a 
GATA-1-DNA complex after TNFα treatment. Nuclear extracts were prepared from K562 (A), 
HEL (B), and TF-1 (C) cells treated with 10 nM Acla, 40 nM Dox, 30 µM He, or 10 U/mL Epo 
for 3 days in the presence or absence of 20 ng/mL TNFα (T) and/or 100 µg/mL of Remicade (R). 
(One representative result of 3 independent experiments)  
5.4.1.2 Effect of TNFα on GATA-1 binding capacity analyzed by TransAM assay 
In order to confirm and quantify the effect of TNFα on GATA-1 binding activity, we 
performed the TransAM assay. Nuclear extracts from different cell lines (0.25 µg/µL) 
were loaded into each well, allowing GATA-1 to bind to its target sequence which has 
been immobilized in the 96-stripwell plate. The bound fraction was then quantified using 
a spectrocolorimetric assay (see materials and methods).  
Effect of TNFα  on GATA-1 binding capacity in K562 cells by TransAM assay 
To investigate the effect of TNFα on constitutive GATA-1 binding, we treated K562 
cells for three days with increasing concentrations of TNFα (20 ng/mL; 40 ng/mL; 60 
ng/mL; 100 ng/mL). Results showed that binding activity decreased in a concentration 
dependent manner (Fig. 24A).  
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Effect of TNFα  on GATA-1 binding capacity in TF-1 cells by TransAM assay 
Then we analyzed the effect of TNFα on GATA-1 binding activity in TF-1 cells. GATA-
1 binding activity was significantly downregulated after TNFα treatment in Epo-induced 
cells. Remicade abrogated the inhibitory effect of the cytokine (Fig. 24B). 
 
 
Figure 24: TransAM analysis of constitutive and induced GATA-1 binding to the GATA-1 
trapper. (A) 10 µg nuclear extracts were prepared from K562 treated for three days with 20, 40, 
60, or 100 ng/mL TNFα (T). (B) 10 µg nuclear extracts were prepared from TF-1 cells treated 
for three days with 10 U/mL Epo in the presence or absence of 20 ng/mL TNFα (T) and/or 100 
µg/mL Remicade (R). Quantification analyses of the TransAM results are expressed in fold 
changes of the average of 3-5 independent experiments. (*P ≤ .05, ***P ≤ .001) 
 
Binding activity of GATA-1 in TNFα-treated cells was reduced as shown by 
EMSA and TransAM experiments. When compared to western blot results, this 
result was not astonishing per se, suggesting that the decrease in GATA-1 binding 
activity is a result of its downregulation. Nevertheless the downregulation of 
GATA-1 affected the level of GATA-1 binding capacity suggesting an effect on 
transactivation of target genes. 
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5.4.2 Effect of TNFα on transactivation activity of GATA-1  
As erythropoiesis is mainly regulated at a transcriptional level, we then assessed the 
effect of TNFα on transcriptional regulation. We performed transient transfection assays 
using a luciferase construct driven by three consensus GATA-1 sites (pGL3-GATA-
Luc). Renilla luciferase reporter vector used were used as an internal control reporter. 
Effect of TNFα  on transactivation activity of GATA-1 in K562 cells 
Results showed an inhibitory effect of TNFα alone on luciferase activity ass well as in 
combination with Acla. The use of Remicade partially abrogated the inhibitory effect of 
TNFα on transcriptional activation in both untreated and treated cells. Cells, which were 
co-transfected with a GATA-1 expression vector, showed an increase of GATA-1-driven 
reporter gene activity. After TNFα addition, this induction was blocked and thus gave 
hints about a direct effect of TNFα on GATA-1 transactivation (Fig. 25A).  
Effect of TNFα  on transactivation activity of GATA-1 in HEL cells 
Whereas He induced an increase in luciferase expression compared to untreated HEL 
cells, TNFα pretreatment clearly abolished this induction (Fig. 25B). Moreover, TNFα 
had a similar effect on transcriptional activity in non-induced cells. Similar results were 
obtained after transient overexpression of GATA-1 by co-transfection of the pXM-
GATA-1 construct (Fig. 25B). TNFα showed an inhibitory effect on GATA-1 
transactivation.   
Effect of TNFα  on transactivation activity of GATA-1 in TF-1 cells 
In TF-1 cells, nucleofection was performed. Results showed an inhibitory effect of TNFα 
on luciferase activity in Epo-treated cells. Cells, co-transfected with a GATA-1 
expression vector, revealed an increase GATA-1-driven reporter gene activity. After 
TNFα addition, this induction is blocked and thus gives us clues about a direct effect of 
TNFα on GATA-1 transactivation (Fig. 25C). 
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Figure 25: Inhibition of GATA-1 driven promoter activity by TNFα. Standardized luciferase 
activity of cells transfected with pGL3-GATA-Luc or in combination with the expression vector 
pXM-GATA-1 in the presence or absence of 20 ng/mL TNFα (T) and 100 µg/mL Remicade (R) 
prior to 48 hours of treatment with 10 nM Acla in K562 cells (A), 30µM He in HEL cells (B), or 
10 U/mL Epo in TF-1 cells (C). Renilla luciferase reporter vector phRL-SV-40 was used as an 
internal control reporter. Values are reported as the means of three independent experiments. 
(*P ≤ .05, **P ≤ .01, ***P ≤ .001) 
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In agreement with the downregulation of GATA-1 expression and its 
decreased DNA binding activity, TNFα  had a negative effect on the 
transactivation of luciferase reporter gene by a GATA transcription factor. 
The use of GATA-1 expression vector showed that TNFα  inhibited the 
transactivation activity of GATA-1 in the three cell lines independently of the 
inducer used. This suggested that TNFα could affect target genes.  
 
5.5 Effect of TNFα erythroid-specific marker gene expression 
As erythroid specific genes are known target genes of the major erythroid transcription 
factor GATA-1 206-209, and as we saw the inhibitory effect of TNFα on the transcriptional 
regulation of GATA-1, we investigated the effect of the cytokine on some erythroid 
markers. mRNA and protein expressions were analyzed by RT-PCR or qRT-PCR 
analysis and western blot.  
5.5.1 Effect of TNFα  on erythroid marker mRNA expression 
Effect of TNFα  on erythroid marker mRNA expression in K562 cells 
In K562 cells, Acla induced a 4.6 fold increase in EpoR mRNA expression compared to 
the control value, which was decreased after addition of TNFα (Fig. 26A). The results of 
γ-globin mRNA analysis showed a 0.7 fold decrease after TNFα treatment when 
compared to Acla alone. 
Effect of TNFα  on erythroid marker mRNA expression in HEL cells  
In HEL cells, TNFα decreased the constitutive amount of EpoR and γ-globin mRNA in 
uninduced cells. In He-induced HEL cells, a pretreatment with TNFα resulted in a 
decrease of EpoR and γ-globin mRNAs (Fig. 26B). 
Effect of TNFα  on erythroid marker mRNA expression in TF-1 cells  
The effect of TNFα on erythroid specific genes expression was analyzed by performing 
qRT-PCR analysis using primers for distinct erythroid specific markers. Figure 26C 
shows that EpoR, α-globin, γ-globin, ERAF, HMBS, and GPA were significantly 
downregulated, while TFRC mRNA was significantly upregulated after cytokine 
treatment (Fig. 26C).  
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Figure 26: Effect of TNFα on erythroid marker mRNA expression. A) RT-PCR of EpoR and γ-
globin mRNA expression prepared from treated (10 nM Acla) or untreated K562 cells in the 
presence or absence of 20 ng/mL TNFα (T). (One representative result of 3 independent 
experiments) B) RT-PCR of EpoR and γ-globin mRNA expression prepared from treated (30 µM 
He) or untreated HEL cells in the presence or absence of 20 ng/mL TNFα (T). (One 
representative result of 3 independent experiments) C) qRT-PCR analysis expressed in fold 
change of erythroid marker mRNA expression after TNFα treatment of Epo-induced TF-1 cells 
compared to Epo treatment alone. Data are means +/- SD of 5 independent experiments. 
Significance was evaluated by Student t-test. (The relative amounts of mRNA were normalized to 
the housekeeping gene MRPS14) (*P ≤ .05, **P ≤ .01, ***P ≤ .001) 
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5.5.2 Effect of TNFα  on erythroid marker protein expression 
In order to confirm mRNA results, we investigated the effect of TNFα on erythroid 
marker protein expression (Fig. 27-29). We analyzed the effect of TNFα and Remicade 
on γ-globin, EpoR and GPA protein expressions in different cell lines treated with 
distinct erythroid inducers. 
5.5.2.1 Effect of TNFα on γ-globin protein expression 
As it is known that K562 and HEL cells do not express β-globin in K562 and HEL cells, 
we analyzed γ-globin expression 150,210. 
Effect of TNFα  on γ-globin protein expression in K562 cells 
We first analyzed its effect on constitutive γ-globin protein expression. K562 cells were 
treated for 2 to 12 hours with 20 ng/mL TNFα. Our findings showed a decrease of 
constitutive γ-globin protein expression after addition of TNFα in the first 6 hours. This 
effect is even enhanced after 8, 10, or 12 hours (Fig. 27A). Moreover, Acla caused an 
important increase in γ-globin protein, whereas after addition of TNFα, γ-globin 
expression was decreased. Three days of treatment with Dox did not stimulate γ-globin 
protein expression, whereas a simultaneous TNFα addition diminished the γ-globin level. 
He treatment resulted in a γ-globin increase, which was downregulated after cytokine 
addition. In combination with each of the 3 inducers, Remicade reversed the inhibiting 
effect of TNFα, confirming the observed effect of TNFα (Fig. 27B).  
Effect of TNFα  on γ-globin protein expression in HEL cells 
In HEL cells, TNFα had a reductive effect on γ-globin protein expression in both 
untreated and He-induced HEL cells (Fig. 27C). He treatment alone showed an important 
increase (2.9 fold) in γ-globin protein expression compared to control. Remicade reversed 
the inhibitory effect on both constitutive as well as on induced γ-globin protein 
expression compared to the TNFα treated cells (Fig. 27C).  
Effect of TNFα  on γ-globin protein expression in TF-1 cells 
Analyzing TF-1 cells for γ-globin variations revealed an induction of γ-globin protein 
expression after a 3-day treatment with Epo compared to the control. This induction is 
reduced after pretreatment with TNFα (Fig. 27D). The use of Remicade reversed this 
inhibitory effect of the cytokine.  
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Figure 27: Western blot analysis of γ -globin protein expression. 10 µg cytoplasmic protein 
extracts were used. β-actin was used as internal control. A) K562 cells were pretreated with 20 
ng/mL TNFα (T) for 2, 4, 6, 8, 10, or 12 hours. B) K562 cells were pretreated with or without 
Remicade (R) (100 µg/mL) and/or TNFα (T) (20 ng/mL) prior to three days of differentiation 
with 10 nM Acla, 40 nM Dox, or 30 µM He. C) HEL cells were pretreated with or without 
Remicade (R) (100 µg/mL) and/or TNFα (T) (20ng/mL) prior to three days of differentiation with 
30 µM He. D) TF-1 cells were pretreated with or without Remicade (R) (100 µg/mL) and/or 
TNFα (T) (20 ng/mL) prior to three days of differentiation with 10 U/mL Epo. (One 
representative result of 3 independent experiments)  
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5.5.2.2 Effect of TNFα on EpoR protein expression 
Effect of TNFα  on EpoR protein expression in K562 cells 
In order to investigate the inhibitory role of TNFα on constitutive EpoR protein 
expression, K562 cells were treated for 2 to 12 hours with 20 ng/mL TNFα. Indeed 
TNFα had an inhibitory effect on constitutive EpoR protein expression in a time 
dependent manner (Fig. 28A).  
This inhibitory effect of the cytokine persisted for three days as observable for EpoR 
protein expression. Moreover, no matter which inducer used, western blot analysis 
showed a reduction of EpoR protein expression in K562 cells (Fig. 28B). Indeed, in Acla 
treated cells, TNFα revealed a 0.6 fold decrease in EpoR protein (Fig. 28B).  Three days 
treatment with Dox did not stimulate EpoR protein expression, whereas a simultaneous 
TNFα addition strongly diminished the EpoR protein level. Cytokine treatment resulted 
also in a decrease of EpoR protein expression in He-treated cells. In combination with 
each of the 3 inducers, Remicade reversed the inhibiting effect of TNFα (Fig. 28B). 
Interestingly in some cases the use of Remicade even enhanced the expression when 
compared to the corresponding treatment. 
Effect of TNFα  on EpoR protein expression in HEL cells 
In HEL cells, TNFα had a reductive effect on EpoR protein expression in both untreated 
and He-induced HEL cells (Fig. 28C). Remicade rescued the inhibitory effect on both 
constitutive as well as on induced EpoR protein expression (Fig. 28C). 
Effect of TNFα  on EpoR protein expression in TF-1 cells 
Analyzing Epo-induced TF-1 cells for EpoR protein variations revealed a reduction after 
pretreatment with TNFα (Fig. 28D). The use of Remicade permitted to reverse this 
inhibitory effect of TNFα on EpoR protein expression. 
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Figure 28: Western blot analysis of EpoR protein expression. 20 µg cytoplasmic protein 
extracts were used. β-actin was used as internal control. A) K562 cells were pretreated with 20 
ng/mL TNFα (T) for 2, 4, 6, 8, 10, or 12 hours. B) K562 cells were pretreated with or without 
Remicade (R) (100 µg/mL) and/or TNFα (T) (20 ng/mL) prior to three days of differentiation 
with 10 nM Acla, 40 nM Dox, or 30 µM He. C) HEL cells were pretreated with or without 
Remicade (R) (100 µg/mL) and/or TNFα (T) (20ng/mL) prior to three days of differentiation with 
30 µM He. D) TF-1 cells were pretreated with or without Remicade (R) (100 µg/mL) and/or 
TNFα (T) (20 ng/mL) prior to three days of differentiation with 10 U/mL Epo. (One 
representative result of 3 independent experiments) 
    
  
Results 
84 
5.5.2.3 Effect of TNFα on GPA protein expression 
Glycophorins are sialoglycoproteins of the human erythrocyte membrane, which bear the 
antigenic determinants. The goal of investigating the expression of GPA is to see whether 
the TNFα treatment has an effect on the expression of this erythroid specific marker. The 
expression of GPA on differentiated cells is analyzed by using flow cytometry analysis.  
Effect of TNFα  on GPA protein expression in K562 cells 
FACS results showed that GPA expression in K562 cells did not vary significantly after 
TNFα treatment in Acla-, or Dox-treated cells, but TNFα significantly decreased GPA 
protein expression in He-induced K562 cells (Fig. 29A).  
Effect of TNFα  on GPA protein expression in HEL cells 
In HEL cells, TNFα significantly decreased the amount of GPA protein expression after 
He treatment. The mean of three independent experiments revealed a significant 20% 
diminution of He-induced EpoR protein expression after TNFα treatment comparing to 
control cells (Fig. 29B).  
Effect of TNFα  on GPA protein expression in TF-1 cells 
Compared to the control, Epo-induction revealed an increase of 30% of EpoR protein in 
TF-1 cells, which was significantly reduced after addition of TNFα to 16%. The addition 
of Remicade rescued this inhibitory effect to 32% (Fig. 29C). 
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Figure 29: Flow cytometry analysis of GPA protein expression. Histograms showing the 
relative percentage of GPA fluorescence compared to untreated controls (c). Pretreatments with 
100µM Remicade (R) and/or 20 ng/mL TNFα (T) for 1 hour were followed by three days of 
differentiation with 30 µM He in K562 (A), and HEL (B) cells, or 10 U/mL Epo in TF-1 cells (C). 
Values are reported as the means (+/- standard deviation, SD) of three independent experiments. 
(*P ≤ .05, ***P ≤ .001) 
 
TNFα had an inhibitory effect on EpoR and γ-globin mRNA as well as on 
constitutive and induced EpoR, GPA, and γ-globin protein expression in all three 
cell lines independently of the inducer used. Moreover, TNFα had an effect on 
other erythroid markers’ mRNA such as TRFC, ERAF, and HMBS, as shown by 
qRT-PCR analysis in TF-1 cells. The anti-TNFα antibody neutralized the 
inhibitory effect of TNFα. In conclusion, TNFα inhibits erythroid specific gene 
expression whose regulation is known to involve the major erythroid 
transcription factor GATA-1. 
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5.6 Effect of TNFα on signaling pathways involved in erythroid 
differentiation  
In order to investigate the implication of distinct cell signaling pathways in the inhibition 
of erythroid differentiation by TNFα, we investigated the effect of different inhibitors on 
TNFα treated cells, which mainly blocks MEK (U0126, PD98059), PI3K (Ly294002), 
JNK (SP600125), NF-κB (Bay11-7082), and p38 (SB203580) pathways.  
Effect of TNFα  on signaling pathways in K562 cells 
After 3-day treatment with the distinct inhibitors, results showed that the use of 
PD98059, a MEK inhibitor resulted in an increased rate of benzidine positive cells, 
independently of the inducer used. Moreover, by using this inhibitor alone or in 
combination with the inducer, an increased hemoglobinization rate could be observed 
when compared to control or induced cells (Fig. 30A, B, C). 
In Dox-induced TNFα treated cells, the use of another MEK inhibitor, U0126, also 
increased the percentage of benzidine positive cells when compared to DoxT treated cells 
(Fig. 30B). Moreover, in He-induced TNFα treated cells, we also observed an induction 
of hemoglobinized cells after the following inhibitors: U0126 (MEK inhibitor), 
Ly294002 (PI3K inhibitor), SP600125 (JNK inhibitor), Bay11-7082  (inhibitor of NF-κB 
activation) (Fig. 30C).  
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Figure 30: Effect of signaling pathway inhibitors on the inhibitory effect of TNFα on 
hemoglobin synthesis in K562 cells. Cells were pretreated with or without U0126 (10µM), 
Ly294002 (10µM), SP600125 (10µM), Bay11-7082 (µM), SB203580 (10µM), PD98059 (10µM), 
and/or TNFα (T) (20 ng/mL) prior to three days of differentiation with 10 nM Acla (A), 40 nM 
Dox (B), or 30 µM He (C). Values are reported as the means (+/- standard deviation, SD) of 3 
independent experiments.  
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Effect of TNFα  on signaling pathways in HEL cells 
In HEL cells, the use of distinct cell signaling inhibitors in HeT treated cells, showed an 
increase of benzidine positive cells when compared to HeT treated cells alone. Thus an 
increase was observed after the use of the MEK inhibitor (PD98059), or the NF-κB 
inhibitor (Bay11-7082) and the highest rate of Benzidine positive cells were obtained 
after the use of the PI3K inhibitor (Ly294002) (Fig. 31).  
 
 
Figure 31: Effect of signaling pathway inhibitors on the inhibitory effect of TNFα on 
hemoglobin synthesis in HEL cells. Cells were pretreated with or without U0126 (10µM), 
Ly294002 (10µM), SP600125 (10µM), PD98059 (10µM), Bay11-7082  (1 µM), SB203580 
(10µM), and/or TNFα (T) (20 ng/mL) prior to three days of differentiation with 30 µM He. 
Values are reported as the means (+/- standard deviation, SD) of 3 independent experiments.  
 
Effect of TNFα  on signaling pathways in TF-1 cells 
In order to validate the involvement of distinct signaling pathways in the TNFα 
inhibiting effect of erythroid differentiation in Epo-treated TF-1 cells, we used distinct 
cell signaling inhibitors in co-treatment with TNFα. In the presence of the p38 inhibitor 
SB203580, we observed an abrogation of the inhibitory effect of TNFα on hemoglobin 
production as assessed by benzidine staining (Fig. 32).  
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Figure 32: Effect of signaling pathway inhibitors on the inhibitory effect of TNFα on 
hemoglobin synthesis in TF-1 cells. Cells were pretreated with or without U0126 (10µM), 
Ly294002 (10µM), SP600125 (10µM), PD98059 (10µM), Bay11-7082  (1 µM), SB203580 
(10µM), and/or TNFα (T) (20 ng/mL) prior to three days of differentiation with 10 U/mL Epo. 
Values are reported as the means (+/- standard deviation, SD) of 3 independent experiments. 
(**P ≤ .01, ***P ≤ .001) 
 
By using inhibitors of distinct signaling pathways, it seems like there is more 
than one pathway involved in the inhibition of erythroid differentiation by TNFα 
depending on the inducer and the cell line used. As our goal is to understand the 
molecular mechanisms leading to anemia, we will especially focus our attention 
on the signaling pathway involved in the inhibition of erythroid differentiation 
by TNFα in Epo-treated cells. Thus, the p38 inhibitor SB203580 partly reversed 
the inhibitory effect of TNFα on the hemoglobinization rate of Epo-treated TF-1 
cells. 
 
5.6.1 Effect of p38 inhibitor on the inhibition of erythroid differentiation by 
TNFα in TF-1 cells 
5.6.1.1 Effect of SB203580 on p38-phosphorylation and total p38 protein in TF-
1 cells 
We evaluated the role of p38 signaling pathway in TNFα-mediated inhibition of 
erythroid differentiation in Epo-differentiated TF-1 cells. TNFα treatment alone showed a 
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1.8 fold activation of p38 phosphorylation compared to control or Epo treated cells after 
30 min (Fig. 30, lane 8), confirming its ability to rapidly activate p38 phosphorylation. 
Conversely, for short times p38 was not phosphorylated in TF-1 cells in the presence of 
Epo alone. Furthermore, in the presence of Epo, p38 phosphorylation after 10 minutes 
was due to TNFα treatment. Thus, phosphorylation was persistent up to 48 hours (Fig. 
33). Moreover, we noticed a progressive increase in phosphorylated p38 (p38-P) protein 
expression after 8 hours of TF-1 culture in the presence of Epo, without TNFα. 
Nevertheless, p38-P expression remained higher in the TNFα-treated cells during the 
time course experiment. 
 
 
Figure 33: Western blot analysis of phosphorylated p38 (p38-P) and total p38 protein 
expression in Epo-induced TF-1 cells in the presence or absence of TNFα after indicated 
treatment time. 10 µg cytoplasmic protein extracts were used. β-actin was used as internal 
control. As a positive control, cells were treated by TNFα alone for 30 min. (One representative 
result of 3 independent experiments) 
 
5.6.1.2 Effect of SB203580 on GATA-1 protein expression 
Then we analyzed the effect of the p38 inhibitor on the major erythroid transcription 
factor GATA-1. Results show a partial abrogation of the inhibitory effect of TNFα on 
GATA-1 protein expression after the use of the p38 inhibitor. Thus, the use of the p38 
inhibitor (SB203580) pointed to an implication of the p38 pathway in the inhibition of 
erythroid differentiation by TNFα (Fig. 34). 
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Figure 34: Effect of p38 inhibitor (SB203580) on GATA-1 protein expression in Epo-induced 
TF-1 cells. 20 µg nuclear protein extracts were used. β-actin was used as internal control. TF-1 
cells were pretreated with or without TNFα (T) (20 ng/mL) prior to three days of differentiation 
with 10 U/mL Epo. (One representative result of 3 independent experiments)  
 
5.6.1.3 Effect of SB203580 on γ-globin protein expression 
In order to confirm the results obtained for GATA-1 protein expression, we assessed γ-
globin protein expression. Results showed a rescue of the inhibitory effect of TNFα on γ-
globin expression after the use of the p38 inhibitor (SB203580) (Fig. 35).  
 
 
Figure 35: Effect of p38 inhibitor (SB203580) on γ-globin protein expression in Epo-induced 
TF-1 cells. 10 µg cytoplasmic protein extracts were used. β-actin was used as internal control. 
TF-1 cells were pretreated with or without TNFα (T) (20 ng/mL) prior to three days of 
differentiation with 10 U/mL Epo. (One representative result of 3 independent experiments)  
 
These results showed an activation of p38 by TNFα in our cellular model. 
Moreover, it gives first hints about an involvement of this MAPK in the inhibitory 
effect of TNFα on GATA-1 and γ-globin protein expression in Epo-induced TF-1 
cells. 
    
  
Discussion 
92 
6 Discussion  
6.1 TNFα reduces hemoglobin synthesis 
In order to investigate the molecular mechanisms involved in cytokine-dependent 
erythroid inhibition, we investigated the effect of TNFα in three different 
erythroleukemia cell lines, K562, HEL and TF-1. These erythroleukemia cell lines are 
widely used as cellular models to study erythroid differentiation thanks to their ability to 
terminally differentiate in vitro in response to distinct agents. 
K562 and HEL cells were induced to differentiate towards erythroid differentiation using 
three different cellular inducers, including two anthracyclins (Acla, Dox) as well as a 
porphyrine (He), all known as inducers of erythroid differentiation 191,194,211. By 
benzidine staining, we could notice the highest differentiation level for He, followed by 
Acla and Dox. In the HEL cell line hemoglobinization was achieved by He. The rate of 
hemoglobinized K562 and HEL cells induced to differentiate by chemicals was 
comparable to previous results 192,212. In order to work with Epo-responsive cells, we also 
we used the growth factor dependent erythroleukemia cell line TF-1 151,152. Indeed, TF-1 
represented a good cellular model to study erythroid differentiation pathways affected by 
TNFα, because these cells differentiate towards erythroid pathway when cultured in the 
presence of the physiological cytokine Epo 195,213,214. In our differentiation model, 10 
U/ml Epo induced erythroid differentiation in TF-1 cells.  
Then we investigated the inhibitory effect of TNFα on erythroid differentiation in these 
three cell lines after induction with the corresponding agents. Independently of the 
chemical inducer (Acla, Dox, He) or the cell line used, we could reveal a decrease of the 
hemoglobin synthesizing cells after TNFα treatment. Moreover, in TF-1 cells, TNFα 
prevented hemoglobin synthesis induced by Epo signaling pathway. In order to validate 
and generalize our hypothesis that TNFα has an inhibitory effect on erythroid 
differentiation, we also started to explore hematopoietic progenitor cells from umbilical 
cord blood. Using a magnetic cell sorting mechanism, we selected CD34+ cells, which 
are pluripotent hematopoietic stem cells. These can give rise to both the myeloid and 
lymphoid lineage. Treating these cells with a distinct cytokine cocktail including SCF, 
IL-3 and Epo 153, we were able to differentiate them towards the erythroid differentiation 
pathway as shown by benzidine staining. Carlile and colleagues showed the appearance 
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of pronormoblasts at day 7 as well as an increasing level of GPA positive cells, which 
correlated with our results the detection of hemoglobin synthesizing cells after 6-7 days 
of culture 153. Moreover, by investigating the effect of TNFα on these hematopoietic 
progenitor cells, we could see a more and more pronounced inhibition of erythroid 
differentiation over time. In previous studies, indications were already provided that 
TNFα had an inhibitory effect on erythropoiesis in vivo and in vitro 116,121,122, implicating 
roles for both TNFα receptors 87,89,119,215. Similarly, it was shown that another 
proinflammatory cytokine IFN, playing a similar role than TNFα in anemia of chronic 
disease, inhibited human CFU-E cells 216. Moreover, Felli and colleagues confirmed this 
inhibitory effect of IFNγ on CD34+ cells of peripheral blood cells implicating also TNF 
superfamily members in the IFNγ-mediated inhibition of erythroid differentiation 217. 
Interestingly, the transplantation of a Chinese hamster ovary cell line transfected with the 
TNFα gene, led to anemia in nude mice, with a significant decrease in erythroid 
progenitors 120. 
The use of Remicade, a clinically applied anti-TNFα ab, allowed us to restrain the 
inhibitory effect of TNFα on erythroid differentiation to TNFα alone. In patients with 
chronic diseases an inhibition of erythroid precursor cells was reversed by the use of an 
anti-TNFα ab 132,134,218. Furthermore, elevated levels of TNFα and IFNγ were detected in 
the bone marrow of patients with aplastic anemia and the use of an anti-TNF ab resulted 
in an increase in corresponding erythroid colonies 219. These results suggested that TNFα 
inhibited differentiation by affecting key regulators of erythropoiesis, common to the 
three different cell lines and the hematopoietic progenitors, rather than disturbing 
specific molecular mechanisms and signaling pathways activated by inducing agents.  
These results suggested that TNFα inhibited differentiation by affecting key regulators 
of erythropoiesis, common to the three different cell lines and the hematopoietic 
progenitors, rather than disturbing specific molecular mechanisms and signaling 
pathways activated by inducing agents. 
 
6.2 TNFα induced NF-κB activity 
TNFα plays a role in various physiological processes why it is implicated in numerous 
diseases, including cancer 52,56,57. The proinflammatory cytokine TNFα is produced by 
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many cell types, but mainly by macrophages in response to inflammation. Indeed, TNFα, 
activated by a broad range of stimuli, is considered as one of the major mediators of 
inflammation by orchestrating inflammatory responses. As already mentioned, its effects 
are principally mediated through two distinct receptors, before stimulating various 
underlying cell signaling pathways 52. As TNFα was shown to be the most powerful 
activator of NF-κB, which is considered as the link between inflammation and cancer 
55,220, we assessed whether TNFα was able to normally activate the NF-κB transcription 
factor in our cellular model. Results showed that NF-κB binding activity was induced in 
K562, HEL and TF-1 cells after TNFα treatment, whatever the inducer used, and the use 
of Remicade partially or completely inhibited this activation. The most frequently 
described active dimer is p50-p65, which leads to the activation of the so-called 
canonical pathway, and is mainly involved in primary inflammatory responses in 
response to inflammatory cytokines 220. The use of the p50 and p65 antibodies permitted 
us to identify the heterodimer p50/p65, known to be constitutively activated in many 
tumors 55.  
 
6.3 TNFα modulates the expression and regulation of major 
erythroid transcription factors 
During the development of erythrocytes from hematopoietic progenitor cells, cells 
progressively restrict their differentiation potential and establish their lineage-specific 
gene expression profiles, relying on lineage-specific transcription factors. The 
transcription factors important for erythroid lineage development include GATA-1, 
GATA-2, NF-E2, and EKLF. However, Blobel suggested that tissue-specific and 
developmentally correct expression of a given gene is not achieved by a single 
transcription factor, rather unique combinations of cell-type specific and widely 
expressed nuclear factors account for the enormous specificity and diversity in gene 
expression profiles 221. So, in order to decode the effects of TNFα on erythroid 
differentiation, we analyzed the expression patterns of distinct erythroid factor 
transcription factors as well as cofactors. 
The importance of the major erythroid transcription factor GATA-1 is emphasized by the 
fact that knock out mice for GATA-1 gene and mutations result in a maturational arrest 
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and apoptosis of erythroid precursors 8,9,222. Moreover, as GATA-1 was reported to be 
involved in the regulation of virtually all erythroid genes, since they all present several 
GATA sequences as specific binding sites for the GATA family of transcription factors 
in their cis-regulatory regions 223,224, we first investigated the effect of TNFα on this 
major erythroid transcription factor. Results showed a reductive effect of the cytokine on 
constitutive and induced GATA-1 mRNA and protein expression in the three cell lines.  
Indeed, GATA-1 is weakly expressed in quiescent erythroid progenitors, but the 
expression is upregulated during differentiation towards the erythroid pathway 225,226. In 
He-treated K562 or HEL cells, we saw a decrease of GATA-1 expression after TNFα 
treatment, but no overexpression when compared to untreated cells. In fact, our group 
previously showed that He-induced GATA-1 expression was associated to lower and 
transient factor activation 194.  
On the other hand, the transcription factor GATA-2 is also involved in the regulation of 
erythropoiesis. Our study demonstrated a reversal of the erythroid expression pattern of 
GATA-1 and GATA-2 after TNFα treatment in uninduced and induced cells. Indeed, we 
showed an increase in GATA-2 expression, which parallels a decrease in GATA-1 
expression. The balanced expression of GATA-1 and GATA-2 during erythropoiesis is 
an important step of red blood cell differentiation. GATA-2 regulates the development of 
hematopoietic precursors 227, whereas GATA-1 is essential for terminal maturation of 
erythroid cells 9. Furthermore it was shown that GATA-1-dependent repression of 
GATA-2 was regulated via disruption of positive autoregulation and chromatin 
remodeling 228. Epo gene regulation was shown to be negatively controlled by GATA-2 
as well as NF-κB in HepG2 cells in response to hypoxia 229. Moreover, cytokines were 
already shown to stimulate GATA-2 expression in primary human hematopoietic 
progenitor cells 230. Together with our findings, these data suggest that cytokines could 
exert their inhibitory effect on erythropoiesis by up-regulating GATA-2 expression. On 
the other hand, Nakano and colleagues suggested the GATA-2 inhibitor K-11706 as 
therapeutic purposes against anemia of inflammatory diseases and cancer 128. This 
compound partially reverses the inhibition of the Epo gene expression by inflammatory 
cytokines. Nevertheless, as this drug is not specific for GATA-2, GATA-1 might also be 
inhibited and thus final erythroid maturation would not be effective.  
The transcription factor NF-E2 plays a role in hemoglobin synthesis, by controlling 
genes essential for globin and HMBS 26,42,199. EKLF is also required for globin gene 
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expression and was shown to be essential for definitive erythropoiesis since EKLF 
deficient mice succumb to fatal anemia due to a defect in hemoglobin accumulation 
43,231. Interestingly, our results showed a reductive effect of TNFα on both transcription 
factor expressions, which was observed in parallel to the GATA-1 protein reduction in 
all three cell lines. In this context EKLF was shown to be act synergistically with the 
major erythroid transcription factor GATA-1 in erythroid complexes 232.  
We then investigated the effect of TNFα on the corresponding GATA-1 cofactors. In 
fact, GATA-1 is known to be regulated by a number of coregulators, which can act either 
as coactivator, such as FOG-1 or as repressor such as PU.1. FOG-1 is essential for 
normal erythroid development as a cofactor of GATA-1 9,202. It was shown that mice 
lacking FOG-1 die during mid-embryonic development from severe anemia 202. 
Interestingly, analysis of FOG-1 expression showed a decrease in FOG-1 protein level 
after TNFα treatment in differentially induced K562, HEL, and TF-1 cells, which 
correlated with erythroid differentiation arrest. PU.1, which is described as the 
antagonistic master regulator of GATA-1, is responsible for the myeloid lineage 
commitment 18,205,233. Moreover, chromatin immunoprecipitation assays showed that 
GATA-1 and PU.1 can colocalize on promoters, and that these transcription factors 
physically interact by distinct motifs 32,234,235. In order to investigate whether TNFα had 
an influence on erythroid/myeloid cell fate decision, we analyzed its effect on PU.1 
protein expression, but the results did not allow us to reveal any common expression 
patterns in the differentially expressed cell lines.   
The N-finger of GATA-1 not only supplies the stabilization and specificity of DNA 
binding 13,24,25, but is also responsible for the interaction with the cofactor FOG-1 23. As 
the analysis of GATA-1 mutants, defective in FOG-1 binding and subsequent 
identification of compensatory mutations in FOG-1, provided definitive proof that the 
FOG-1/GATA-1 interaction is essential for GATA-1 function during erythropoiesis 35, 
we investigated the effect of TNFα on GATA-1/FOG-1 interaction by 
immunoprecipitation. Results showed that GATA-1 and FOG-1 were linked together in 
the untreated or He-induced HEL or Epo-treated TF-1 cells since they co-
immunoprecipitated. After TNFα addition, the co-immunoprecipitation revealed a 
decrease in the amount of both interaction partners and a suppression of the GATA-
1/FOG-1 complex in uninduced HEL cells after TNFα addition. This suggested that the 
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interaction between GATA-1 and FOG-1 was not significantly affected in differentiated 
cells. The decrease of the complex could be due to an inhibition of the expression of the 
interaction partners, which could involve an inhibitory effect of TNFα on the 
transcriptional level and/or an increase of protein degradation. The use of the proteasome 
inhibitor lactacystin confirmed an ubiquitin-proteasome signaling pathway dependent 
degradation of FOG-1 and/or GATA-1 after TNFα treatment in differentiated cells. To 
our knowledge, no data were reported concerning FOG-1 degradation by proteasome and 
this phenomenon should be investigated in the future. On the other hand, it is reasonable 
to think that the inhibitory effect of TNFα occurs at the transcriptional level of GATA-1 
gene expression since GATA-1 mRNA and protein amount is reduced in the presence of 
TNFα, and that GATA-1 protein decreased even when proteasome was inhibited. 
Interestingly, Lurie and colleagues recently described that differential GATA-1 and 
GATA-2 factor stabilities regulated by proteasomal regulation represent an important 
determinant of chromatin target site occupancy and thereby altering the gene expression 
profile of erythroid precursors as an essential step in erythropoiesis 50. Cantor and 
colleagues recently suggested a cross-antagonistic regulatory loop between GATA-2 and 
FOG-1, where high GATA-2 levels lead to FOG-1 repression 236, what could be in line 
with our results. Furthermore it was shown that FOG-1 facilitates GATA-1 chromatin 
occupancy and GATA-2 removal at chromatin sites bound by GATA-2 237. Another 
interesting study shows that GATA factor exchange reconfigures higher chromatin 
organization involving chromatin loop changes 238. 
Another important posttranslational modification of GATA-1 consists of its acetylation 
by CREB-binding protein (CBP) 30,45. Interestingly, previous results showed that 
acetylation-defective GATA-1 binds DNA normally in vitro as shown by EMSA assay 
but fails to bind physiologic target genes in vivo 239. Moreover, Hernandez-Hernandez 
and colleagues even proposed a model showing that GATA-1 acetylation is essential for 
DNA binding and a subsequent GATA-1 phosphorylation marks the protein for 
subsequent proteasomal degradation 48. Our immunoprecipitation results showed an 
inhibition of GATA-1 acetylation by TNFα in He-induced K562 cells, suggesting that 
TNFα could have an influence on erythroid gene transcription.  
Overall, the reduction of the amount of GATA-1/FOG-1 complex as well as the 
modulation of GATA-1 acetylation should have consequences on erythroid gene 
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transcription since GATA-1, NF-E2, EKLF, and FOG-1 were downregulated while 
GATA-2 transcription factor was over-expressed in TNFα treated cells.  
 
6.4 TNFα inhibits GATA-1 transactivation activity 
Acla was previously shown to act by activating transcription of erythroid specific genes 
in association with prolonged increase of GATA-1 DNA binding activities 191,192,211. In 
our study GATA-1 binding activity was reduced after TNFα addition independent of the 
inducer or the cell line used. TransAM confirmed the inhibitory effect of TNFα on 
erythroid differentiation and showed a concentration dependent reductive effect of TNFα 
on constitutive GATA-1 binding activity in K562 cells. EMSA and TransAM results 
indicated that Dox did not induce GATA-1 binding when compared to the control, 
whereas the binding activity was reduced when treated in combination with TNFα. This 
observation is in agreement with prior results, where the existence of a Dox-specific 
differentiating mechanism was proposed, based on posttranscriptional regulation 
mechanisms of erythroid gene expression 192,211. Moreover, EMSA results obtained after 
He treatment were similar to the western blot results, where no increase of GATA-1 
binding activity was noted in He-induced K562 cells after three days of treatment 
suggesting a transient GATA-1 activation 194. By adding Remicade, this inhibitory effect 
of TNFα was abrogated. Furthermore, TNFα abolished GATA-1 transcription activity as 
shown by transfections. The results of this study using three different cell lines could 
indicate a general trend of TNFα to inhibit erythroid differentiation.  
 
6.5 TNFα has an effect on erythroid markers 
Thus, in order to confirm this transcriptional modulation by TNFα on a phenotypic level, 
we analyzed distinct erythroid markers, known to be regulated by GATA-1, and other 
erythroid transcription factors such as NF-E2 or EKLF 26,42,199. In Epo-induced TF-1 
cells, analysis of a panel of erythroid genes showed a significant decrease in EpoR, α-
globin, γ-globin, ERAF, HMBS and GPA erythroid specific marker mRNAs after TNFα 
addition. The TFRC gene expression was increased in agreement with its current use as 
an index of tissue iron deficiency in anemic patients with cancer or inflammation 240. The 
inhibitory effect of TNFα on erythroid gene expression was confirmed on Epo receptor 
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(EpoR), γ-globin and GPA protein levels in all three cell lines independently of the 
inducer used. After long discussions on the detection of EpoR in distinct studies, the M-
20 ab permitted us to observe reproducible decreases in EpoR protein expression after 
TNFα treatment 241. Interestingly, after Remicade addition, the analysis of EpoR or γ-
globin protein expression showed sometimes an overexpression of the protein, when 
compared to corresponding treatments without Remicade. This observation could be due 
to the fact that erythroid cells were shown to express TNFα. Indeed Jacobs-Helber and 
colleagues already reported that TNFα is constitutively expressed in erythroid cells 242. 
Xiao and colleagues showed that GPA positive generation was inhibited in TNFα treated 
human CD34+ progenitor cells 129. Overall we can conclude that these three erythroid 
genes (GPA, globin and EpoR) could represent efficient erythroid markers in the 
detection of cytokine dependent anemia.  
 
6.6 TNFα involves the p38 pathway in the inhibition of Epo-
induced erythroid differentiation 
By using inhibitors of distinct signaling pathways, results showed that depending on the 
inducer and the cell line used, more than one pathway seemed to be involved in the 
inhibition of erythroid differentiation by TNFα depending on the inducer and the cell line 
used. The use of the inhibitor of NF-κB, Bay11-7082, did not permit us to draw any 
general conclusions in the differentially induced cell lines despite of some data 
suggesting an involvement of the NF-κB signaling pathway during erythroid 
differentiation 196, as well as during the inhibition of erythroid differentiation 129,229.  
As the aim of this study is to understand the molecular mechanisms leading to anemia, 
we wanted to especially focus our attention on the signaling pathway involved in the 
inhibition of erythroid differentiation by TNFα in Epo-treated cells. During erythroid 
differentiation, p38 isoforms p38α and p38γ were already reported to be expressed 243, 
which is in agreement with our results concerning total p38 expression. Moreover, p38 as 
well as JNK, are known to be activated by Epo and are required for Epo-induced 
erythropoiesis 242,244. Moreover, Tamura and colleagues showed a defect in definitive 
erythropoiesis in p38-/- mice embryos due to an Epo deficiency 245. TNFα is known to 
activate various signaling pathways leading, amongst others, to p38 activation through 
TNFRI/II, TNFR-associated death domain (TRADD), TNFR-associated factor 2 
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(TRAF2), receptor-interacting protein (RIP), MAP/ERK kinase kinase 3 (MKK3) 52,246. 
Using the p38α isoform inhibitor SB203580, we observed an abrogation of the inhibitory 
effect of TNFα on erythroid differentiation as shown by hemoglobin, γ-globin and 
GATA-1 upregulation. Interestingly, the differentiating inhibitor TNFα and the activator 
Epo are both described being capable to stimulate p38 phosphorylation. Results showed 
that TNFα treatment combined to Epo induced strong p38 phosphorylation after only 10 
min, while in the presence of Epo alone, this phosphorylation in only observed after 8 
hours. The effect of Epo was amplified over time, an effect already reported in 
differentiating Apicidin-induced K562 cells 247. Moreover, TNFα-induced 
phosphorylation was also observed after 30 min in the absence of Epo, eliminating the 
hypothesis that cotreatment would amplify p38 activation. The inhibition of erythroid 
differentiation by TNFα seems to be dependent on p38 pathway in TF-1 cells and to 
occurs in correlation with an early activation of p38. Interestingly, inhibition of GATA-1 
expression was shown to be dependent on p38 signaling pathway, and probably 
independent of proteasomal degradation. Stassen and collegues even postulated GATA-1 
as a target for p38 mediated phosphorylation in mast cells 248, a posttranslational 
modification, which is still controversially debated concerning its importance in DNA 
binding 46,249. Interestingly, Miwatashi and collegues already used a novel p38 inhibitor, 
N-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl] benzamide (TAK-715), as 
an anti-TNFα drug for the treatment of rheumatoid arthritis patients 250, known to be 
susceptible for anemia 134.  
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In conclusion, our results provide first evidence that TNFα inhibits erythroid 
differentiation by downregulating key transcription factors such as GATA-1, NF-E2, and 
EKLF. Furthermore, we showed that TNFα-mediated inhibition of GATA-1 involved the 
p38 MAPK pathway. Downregulation of GATA-1 and its cofactor FOG-1 lead to a 
diminished GATA-1/FOG-1 forming complex. This inhibition correlated with a 
proteasomal degradation of both interaction partners. Moreover, TNFα abolished the 
acetylation status of GATA-1, which was correlated to an inhibition of GATA-1 
transcriptional activity resulting in a reduction of GATA-1 regulated erythroid genes. In 
addition we observed a simultaneous upregulation of GATA-2 in accord with a reduced 
hemoglobin production as well as decreased erythroid marker genes expression in both 
chemical- and Epo-induced cells. Overall these results give first insights of the major 
changes involved in the inhibition of erythroid differentiation by a key mediator of 
inflammation. This might serve as a solid base for future investigations in finding 
potential therapeutic targets for inflammation and cancer related anemia. 
 
Figure 36: Scheme summarizing the effect of TNFα  on erythroid differentiation based on the 
results obtained for TF-1 cells.
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ab antibody 
Acla Aclacynomicin A 
AML acute myeloid leukemia 
Baso EB basophilic erythroblasts  
BCP B-cell progenitor 
BFU-E erythroid burst-forming units  
BSA bovine serum albumin 
C control 
CFU-E erythroid colony-forming units  
CLP common lymphoid progenitor 
CML chronic myeloid leukemia 
CMP common myeloid progenitor 
DEPC diethylpyrocarbonate 
DMSO dimethyl sulfoxide 
Dox Doxorubicin 
DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen 
DTT 1,4-Dithiothreitol 
EDTA ethylene-diamin-tetra-acetat 
EKLF erythroid Kruppel-like factor   
EMSA electrophoretic mobility shift assay 
Epo erythropoietin 
EpoR erythropoietin receptor 
ERK extracellular signal-related kinase 
FA Fanconi anemia 
FCS fetal calf serum 
FITC fluorescein isothiocyanate  
FOG-1 Friend of GATA-1 
G-CSF granulocyte colony-stimulating factor 
GM-CSF granulocyte-macrophage colony-stimulating factor 
GMP granulocyte–macrophage progenitor 
GPA Glycophorin A 
He  Hemin 
H2O2 hydrogen peroxide 
HCl chlorhydric acid 
HEL human erythroleukemia cell line 
HIF hypoxia-inducible factor  
HSC pluripotent hematopoietic stem cell 
IκB inhibitor of NF-κB  
IKK Inhibitor of kappa B kinase 
IFN Interferon 
IL Interleukin 
     
  
Abbreviations 
119 
JAK Janus kinase 
JNK c-Jun N-terminal kinase  
MACS magnetic cell sorting 
MAPK mitogen-activated protein kinase 
M-CSF macrophage colony stimulating factor 
MEK mitogen-activated protein kinase MAPK kinase  
MEP megakaryocyte erythroid progenitor 
MKK MAP/ERK kinase kinase 
MPP multipotent progenitor 
MW molecular weight 
NF-E2  nuclear factor erythroid-2 
NF-κB nuclear factor kappa B 
O/N overnight 
OD optical density 
Ortho EB orthochromatic erythroblasts 
PBS phosphate buffered saline 
PCR  polymerase chain reaction 
PerCP peridinin chlorophyll A protein 
PI3K phosphoinositide-3 kinase 
Poly EB polychromatophilic erythroblasts  
Pro EB proerythroblasts  
qRT-PCR quantitative real-time RT-PCR 
R Remicade 
RBC erythrocytes  
RET reticulocytes  
rcf relative centrifugal force  
rhuEpo Recombinant human erythropoietin  
RIP receptor-interacting protein 
RT reverse transcriptase 
SCF stem cell factor 
SD standard deviation 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide electrophoresis 
STAT signal transducer and activator of transcription 
T Tumor necrosis factor alpha 
TFRC transferrin receptor 
TNFα Tumor necrosis factor alpha 
TNFR Tumor necrosis factor alpha receptor 
TNK T-cell natural killer cell progenitor 
TPO thrombopoietin 
TRADD TNFR-associated death domain 
TRAF2 TNFR-associated factor 2 
Tris Trishydroxymethylaminomethane 
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